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Abstract
The aim of this dissertation is to understand peptide sorption to PLGA, with the goal of
stabilizing octreotide against acylation within PLGA. These studies describe the first detailed
investigations of peptide sorption to low Mw free-acid PLGA. A new class of inhibitors
of the sorption and acylation of a model peptide, octreotide, has been described. Long-
term sorption studies indicated that CaCl2 and MnCl2 disrupt peptide sorption to PLGA
with the inorganic divalent cation inhibitors translates to inhibition of peptide acylation.
The octreotide-PLGA interactions are mostly irreversible in aqueous solution and strongly
increase solubility of octreotide in acetonitrile. Only the addition of solvent or 5% SDS
resulted in a substantial desorption from PLGA, strongly suggesting the irreversibility is
due to hydrophobic interactions or hydrogen-bonding between the peptide and PLGA.
The kinetics of peptide sorption to PLGA was studied and well described using a biex-
ponential model. Sorption is reduced at low octreotide concentrations, high ionic strength
and low temperature, suggesting polymer mobility plays a critical role in the sorption in-
teraction. Although irreversible, peptide sorption follows Langmuir behavior. Sorption of
octreotide decreased as the pH of the solutions tested was decreased toward the pKa of
PLGA carboxylates. Reducing the number of total acid end-groups by increasing the PLGA
molecular weight also decreased octreotide sorption. These results indicate the critical role
of ionized PLGA acid end-groups during the peptide sorption pathway. Quantification of
the maximal amount of peptide sorbed at high solution concentration showed this value
to be similar to the total number of PLGA acid end-groups for RG502H and RG503H.
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The low amount of sorption to the higher molecular-weight RG504H is also consistent
with peptide partitioning into the polymer phase. Film sectioning after peptide sorption
showed a proportional decrease in peptide remaining in the polymer with fraction of film






Biodegradable controlled-release systems for the delivery of biological therapeutics pro-
vides the opportunity to enhance patient acceptability, compliance, and outcomes relative
to parenteral formulations typically used currently. The stability of peptides and proteins
within poly(lactic-co-glycolic acid) (PLGA) microspheres and implants has been identified
as a major challenge for the successful development of PLGA controlled release systems.
Significant resources have been committed to gaining a mechanistic understanding of the
physical and chemical instabilities of peptides and proteins in the solution- and solid-states,
as well as at phase interfaces.
The acylation of amine-containing molecules with PLGA is a deleterious chemical
reaction that could compromise drug purity, efficacy, and safety. Compared to other in-
stability pathways, such as aggregation or deamidation, which have been investigated for
decades by a large number of research groups, significant contributions towards a complete
understanding of the peptide acylation pathway with PLGA have only recently been devel-
oped by a few research groups. Although progress has been made to clearly demonstrate
acylation of peptides in PLGA, there remain significant mechanistic questions unanswered.
For examples, it is still unclear what role primary or higher order structure plays on the rate
and extent of peptide acylation. It is also unclear in which phase acylation occurs— whether
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at the interface between the aqueous solution and the polymer or whether the peptide has
limited solubility in the bulk. Is it possible that the low molecular weight polymer has some
solubility for the peptide? There appears to be a relationship between octreotide sorption
and acylation in PLGA. What factors govern peptide sorption to PLGA? If the questions pre-
viously described were answered, there is a reasonable possibility of significantly inhibiting
the acylation reaction in PLGA.
1.2 Overview
In this dissertation, peptide acylation with PLGA is investigated in detail, with an emphasis
on understanding the reaction mechanistically and utilizing this understanding to develop a
rational inhibition strategy. Our specific aims are to evaluate excipients and conditions that
inhibit acylation, investigate how peptide or PLGA properties effect sorption and acylation,
and ascertain whether the peptide interacts with PLGA by via multilayer formation or by
absorbing into the bulk polymer phase.
Chapter 1 provides motivation for carrying out the research described within this thesis.
Chapter 2 provides background on the therapeutic delivery of peptides and proteins, includ-
ing an overview of several non-parenteral delivery technologies, with a focus on PLGA
controlled release systems. The stability of peptides and proteins in PLGA, one of the key
challenges in controlled release systems, is also reviewed. The the acylation reaction and
literature reports of peptide acylation are reviewed in detail.
A general introduction to the experimental system and methodology is presented in
Chapter 3. More detailed experimental protocols can be found in the relevant individual
chapters.
Chapters 4, 5, 6, and 7, containing the bulk of the experimental data of this dissertation
have been written an a manner that allows them to be read individually as ’stand-alone’ doc-
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uments, to the extent that it was possible. As a result, there is a small amount of redundancy
in certain sections.
Chapter 4 presents a new method to inhibit acylation involving disruptors of peptide sorp-
tion, namely, water-soluble inorganic divalent cations salts. The effect of divalent cations
on the kinetics of sorption and 24-hr sorption isotherms of a model peptide, octreotide
acetate, to free-acid end-group PLGA was monitored to determine theer order and absolute
effectiveness on inhibition of acylation.
In Chapter 5, we study the effect of initial concentration and ionic strength on the kinetics
of peptide sorption to PLGA, investigate the rate-limiting step, compare the sorption kinetics
of two model peptides, octreotide and leuprolide, which have different structures, net charge,
and conformational flexibility, and present a biexponential kinetic model that describes the
sorption process well.
In Chapter 6, the characteristics of peptide sorption to PLGA, such as the stoichiometry,
binding affinity, and maximal amount of peptide sorbed, 24-hour sorption iostherms were
obtained for two model peptides, octreotide and leuprolide. Although octreotide sorption
to PLGA is found to be essentially kinetically irreversible in aqueous solutions, the data
follows Langmuir-like behavior; a modified Langmuir isotherm is used to estimate the
maximum amount of peptide sorbed and show that this value is roughly equal to the total
acid content of the polymer.
Chapter 7 investigates the localization of octreotide sorbed to PLGA. Several studies are
performed to learn whether octreotide sorption is primarily surface-associated or whether
partitioning into the bulk polymer phase occurs.
Chapter 8 summarizes the important results and contributions of this work.
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Chapter 2
Background: Therapeutic delivery of
peptides and proteins
The development of recombinant DNA technology in the 1970s and the success of the
human genome project in the 1990s have made discovery and large-scale production of
biological therapeutics possible. More than 325 million people worldwide have been helped
by the more than 155 biotechnology drugs and vaccines approved by the U.S. Food and
Drug Administration (FDA) [1]. Numerous peptide and protein therapeutics are now indi-
cated for treatment of life-threatening diseases previously untreatable with low-molecular
weight drugs—insulin for diabetes, erythropoietin for anemia, growth hormone for dwarfism,
interleukins and interferons for cancer and multiple sclerosis, vaccines, and monoclonal
antibodies for cancer, Crohns disease, immunosupression, etc. There are also more than
400 biotechnology drug products and vaccines currently in clinical trials targeting more
than 200 diseases, including various cancers, Alzheimer’s disease, heart disease, diabetes,
multiple sclerosis, AIDS and arthritis [1]. The biotechnology industry has grown rapidly
since 1992, with revenues increasing from $8 billion in 1992 to $58.8 billion in 2006 [1].
The successes of the biotechnology industry, however, have not been matched by progress
in the formulation and development of peptide and protein therapeutics [2, 3, 4, 5, 6]. In
many cases, the successful development of formulation and delivery methods has been the
bottleneck for their wide spread use. As the number of biotechnology drug products moving
through the pipeline increases, the significance of the development of a generic formulation
and delivery strategy has become paramount.
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Oral delivery is the preferred method for most patients because it is simple, convenient,
and familiar. Unlike traditional small molecule therapeutics, proteins are large, hydrophilic
molecules with many labile bonds and side chains as well as a higher order structure that
if perturbed can lead to reduced activity or immunogenicity [7]. The development of a
successful oral polypeptide formulation has been limited by several factors: chemical insta-
bility due to extreme pHs in the digestive tract, susceptibility to enzymatic degradation by
proteases, low permeability across the intestinal epithelial membrane as a result of proteins
charge, hydrophilicity, and high molecular weight, and rapid post-absorptive clearance [7, 8].
For these reasons, most biological therapeutics currently on the market are formulated for
parenteral administration.
Parenteral administration of proteins can be painful and inconvenient for patients. Fur-
thermore, plasma half-life of proteins and peptides can vary dramatically. Many, for example
cytokines, have half-lives on the order of minutes [9], requiring multiple injections per day
or an infusion to obtain therapeutically effective drug levels. The use of other, more non-
invasive delivery routes could increase ease of use and patient compliance, especially in
an out-patient setting, as well as offer delivery options such as site-specific delivery and/or
controlled release. Potential minimally invasive protein delivery methods that have re-
ceived substantial interest include oral, nasal, transdermal, pulmonary, and buccal routes.
Unfortunately, success in these areas has been limited and a general method has not yet
been developed. The advantages and disadvantages of three of the more widely researched
potential delivery routes will be discussed, followed by a description of controlled release
technology and its clinical applications.
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2.1 Oral Delivery
The development of an oral protein formulation has been hindered by several factors, namely
low epithelial permeability and instability in the GI tract. Due to the potential benefits of
successful oral formulations, substantial research has been aimed at developing methods to
overcome the barriers to oral delivery of biopharmaceuticals. Two major approaches have
been to increase permeability of either the epithelium or the protein drug or to protect the
protein from the extreme pH and proteolytic enzymes in the stomach and duodenum.
Several types of penetration enhancers have been studied, such as bile salts, fatty acids,
and surfactants [9]. The use of these molecules to enhance the permeability of epithelium
suffer many drawbacks, particularly damage to the epithelium, the unacceptably high con-
centrations necessary, the potential for increasing absorption of toxins, and the dilution of
the permeability enhancer in the GI tract when localized delivery of the entire formulation
is needed at epithelium surface [8].
Enhancing the permeability of the polypeptide can be done using carrier molecules
that are either covalently attached or interact non-covalently. Covalently linked molecules,
such as vitamin B12, can target proteins to membrane transporters, where the protein is
absorbed via active transport (transcytosis) [10]. The permeability of proteins can also be
increased by covalently linking a lipophilic molecule. An example of this is hexyl-insulin
monoconjugate-2 (HIM2), developed by Nobex [11]. The former method is limited by
the density of receptors, while both methods result in increased complexity and cost of
manufacturing due to the difficulty in linking the attachment to the protein without altering
its activity. Furthermore, the covalent attachment must be labile, so that it is easily removed
from the peptide upon absorption. Another approach to increase permeability, developed
by Emisphere, uses small amphiphilic carriers that interact non-covalently with proteins,




The pulmonary route of administration is attractive because it is non-invasive, it has been
successfully utilized for the delivery of several traditional small molecule drugs, and it
has received encouraging results for the delivery of some proteins. Pulmonary delivery is
particularly advantageous in cases where the lungs are the intended site of drug delivery, for
example the use Pulmozyme R© (recombinant human deoxyribonuclease (rhDNase)) to treat
cystic fibrosis. However, the potential for local toxicity must be considered in cases where
systemic delivery via the lungs is desired [13]. The large contact area with blood vessels in
the alveoli of the lungs leads to rapid, bolus-like drug absorption. This is desirable for drugs
like insulin, where the rapid onset of a peak serum level is necessary prior to meals, but may
not be acceptable for other peptides or proteins with a narrow therapeutic index and short
serum half-life.
Unfortunately, the bioavailability of inhaled protein formulations varies substantially,
between 0-60% [13, 14]. Pulmonary bioavailability depends on the efficiency of the inhala-
tion device, the fraction of drug that is deposited in the lung, and the fraction of drug that is
absorbed from the alveoli. Current aerosol devices deliver drugs into the lungs at efficiencies
on the order of 20% with significant dose to dose variability [15]. For example, Cipolla
et al. evaluated four types of jet nebulizers for the pulmonary delivery of Pulmozyme R©,
and found an average delivery of rhDNase of 25% to the mouth-piece [16]. Only a fraction
of the dose delivered to the mouth actually enters the lungs. Furthermore, the efficiency
of alveolar absorption is low and can vary from protein to protein [14] as well as among
individuals for several reasons, such as differences in breathing patterns or due to smoking.
Such variations are unacceptable for proteins with a narrow therapeutic index.
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2.3 Transdermal Delivery
Another potential route of administration is the transdermal delivery of biological molecules.
Successful transdermal delivery would avoid inconveniences of parenteral therapy, permit
continuous drug delivery at a controlled rate, useful for drugs with a short half-life and/or a
narrow therapeutic index, and permit rapid termination of delivery [17]. Human skin, how-
ever, is an excellent barrier to the outside, severely limiting transdermal delivery, especially
for proteins, which have high molecular weights and are hydrophilic. An ideal candidate
for transdermal delivery is potent, has low molecular weight, and is slightly lipophilic [18].
However, considering the hundreds of approved drugs, many with all three characteristics,
only about ten small molecules are currently marketed for transdermal delivery [19].
The key to overcoming the skins barrier function for drug delivery is to disrupt the
stratum corneum, the outermost layer of the skin consisting of dead cells surrounded by
lipids. Several methods exist to permeate the skin by disrupting the stratum corneum, such
as iontophoresis (small electric current), electroportation (short, high-voltage pulses), and
sonophoresis (ultrasound) [19]. Mitragotri et al. have shown that insulin (∼6000 kDa),
interferon-α (∼17000 kDa), and erythropoietin (∼48000 kDa) can be transported across the
epidermis in vitro at rates that are therapeutically useful using low frequency ultrasound,
although variations in the data were significant (22-40%) [20]. Nevertheless, the safety of
skin permeation methods such as low-frequency ultrasound has not been validated. Methods
such as iontophoresis can denature proteins and irritate the skin, sometimes leaving a rash
and eliciting a harmful immune response [21]. Another disadvantage of transdermal delivery
is the large number of enzymes and macrophages in the epidermis that can degrade peptides
prior to their absorption, further decreasing bioavailability.
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2.4 Controlled Release Depots
Traditional delivery systems for biological therapeutics administer the entire dose of drug in
one bolus resulting in high, sometimes near-toxic, plasma levels. Since most therapeutic
proteins, such as hGH [22] and cytokines [9], have short half-lives, repeated administra-
tion of large doses is often necessary to maintain therapeutically effective levels. Depot
delivery systems offer the advantage of a continuous, zero-order release profile similar
to that of an infusion. This could eliminate side-effects from repeated injections of large
doses such as fever, diarrhea, anorexia that is observed with some proteins, for example
IL-1α [9]. Furthermore, controlled release of vaccine antigens could eliminate the need
for repeated immunizations, resulting in increased patient compliancean important issue
in many underdeveloped countries [23, 24]. Currently, several peptide controlled release
formulations, including Lupron Depot R© (leuprolide acetate), Sandostatin R© (octreotide ac-
etate), and Zoladex R© (groselin acetate). These formulations can deliver peptide therapeutics
continuously over a period up to six months [25], eliminating the need for daily injections.
Controlled release systems can also be used to deliver proteins in a site-specific manner.
This is advantageous for proteins such as cytokines (IL-2, TNF-α) or growth factors (bFGF,
VEGF [26], BMP [27]), where systemic toxicity occurs at the high levels necessary for local
efficacy [28]. Polymeric microparticles have uses in many different site-specific applications.
For example, they can be implanted in discreet locations of the brain using stereotaxy [29]
to deliver neutrophins (NGF, BDNF, CNTF) for the treatment of neurological degeneration
and Alzheimers [30]. Microspheres can also be surface modified with a ligand to target them
to specific receptors on cells [31]. Biodegradable nanoparticles have beeen utilized for oral
delivery of antigens. These nanoparticles are taken into the lymphatic system by M cells
in Peyers patches, inducing immune response [31]. Recently, drugs have been loaded onto
stents using degradable polymeric coatings to prevent restenosis [32]. Biodegradable micro-
spheres containing growth factors have also been incorporated into scaffolds to facilitate
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growth and vascularization of new tissues to replace damaged or diseased tissues [33, 34].
Controlled release has been achieved with both non-degradable and degradable deliv-
ery systems. The use of non-degradable polymers in implantable applications, such as
poly(ethylene-co-vinyl acetate) (EVA) and silicone rubber, often has been limited to use for
long term delivery (several years) because these materials should be surgically removed. On
the other hand, biodegradable polymers, such as polyesters and polyanhydrides, are much
more desirable since they are naturally degraded and eliminated by the body. Furthermore,
drug release from degradable polymers is erosion-controlled, resulting in slower release
than for diffusion-controlled non-degradable polymers. Many degradable homo-polymers,
copolymers, and polymer blends have been studied for potential use in controlled release
depots. Among them, the homo- and co-polymers of lactic and glycolic acid (PLA, PGA,
and PLGA, respectively) have been the most widely studied. PLGAs are biocompatible and
their degradation end products, lactic and glycolic acid, are incorporated into the TCA cycle
or eliminated in the urine [35]. PLGA has a long history of surgical use, having been used
as a resorbable suture material for over 30 years [36] and is the only biodegradable polymer
approved by the FDA for use in humans.
2.4.1 Physical and Chemical Properties of PLGA
The structures of poly(glycolic acid), poly(L-lactic acid), and poly(D,L-lactic-co-glycolic
acid) are shown in Figure 2.1. The pKa of LA and GA are 3.86 and 3.83, respectively, at
25◦C. Lactic acid differs from glycolic acid by an additional methyl group. Because of
this, lactic acid contains an asymmetric carbon and has two stereoisomeric forms. Due to
the stereochemistry of lactic acid, several types of PLGAs can be fabricated: poly(L-lactic
acid), poly(D,L-lactic acid), poly(glycolic acid), poly(L-lactic-co-glycolic acid), and poly
(D,L-lactic-co-glycolic acid). PLGAs with racemic mixtures of lactic acid are generally
referred to as PLA or PLGA, while those containing only one isomer of lactic acid will
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Figure 2.1 The structure of the PLGA family of polyesters.
contain an additional L or D in its abbreviation to specify the stereochemistry (e.g. PLLA,
PDLA, PLLGA).
PLGA can be synthesized from LA and GA monomers by step-growth polymerization or
by condensation using cyclic dimers. The former process is not frequently used because the
production of PLGA with MW larger than 10,000 Da is impractical due to the difficulty of
removing water [37]. Condensation from cyclic dimers, however, can easily produce PLGA
with molecular weights of 100,000 Da using organometallic catalysts such as stannous
octoate [37].
PLGA characteristics can be modified by adjusting the monomer stereochemistry,
monomer ratio, molecular weight, polymer chain linearity, and end-capping. Monomer
stereochemistry affects the crystallinity, melting point, and solubility of PLGA. The stere-
oregular homopolymers PLLA and PGA are crystalline, have a high melting point, and
are only soluble in more aggressive solvents. Racemic mixtures of lactic acid (PLA) and
PLGA are amorphous, do not have a true melting point, and are soluble in less aggressive
solvents. The hydrophobicity, glass transition temperature (Tg), and degradation half-life
increase as the LA:GA ratio increases. Lactic acid is more hydrophobic than glycolic acid
because of its additional methyl group. Thus, water uptake is decreased for PLGAs with
higher LA:GA ratios, resulting in lower rates of hydrolysis. The Tg of PLA and PGA are
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55-60◦C and 35-40◦C, respectively, while the Tg of PLGAs is intermediate between the
two, increasing with increasing LA. The Tg of LA is higher than that of GA because the
additional methyl group decreases the free volume and chain flexibility [38]. Similarly, the
Tg also increases with molecular weight due to decreased chain flexibility. At physiological
temperature, PLGA microspheres with a typical Tg ∼45◦C will be in the glassy state in the
absence of solvent (water). Upon incubation in an aqueous environment, the Tg of the micro-
spheres with sufficiently low molecular weight will decrease and they will become rubbery
at physiological temperature (37◦C) due to the plasticization effect of water [39, 40]. Park
[39] has shown that the Tg of PLA microspheres with Mw = 17 and 41 kDa decreases from
41.7 and 47.0◦C, respectively, to 34.2 and 39.4◦C, respectively after two days incubation at
37◦C. Subsequently, Blasi et al. [40] found that the Tg of RG503H decreases from 45 GA
27◦C after one day incubation at 37◦C. In most cases, microspheres in the rubbery state are
preferred because the increased permeability of water and water soluble species is desirable.
PLGA Mw and polydispersity (Mw/Mn) also affect degradation rate and intrinsic viscos-
ity, which are important for release from, and manufacture of, microspheres, respectively. As
PLGA Mw decreases and polydispersity increases, the number of acids chain ends decreases,
affecting the pH inside microparticle pores. PLGA carboxylic acid chain ends may be
modified by end-capping. Common end groups include lauryl or methyl esters. The addition
of end groups affects PLGA hydrophilicity, solubility, and increases the Tg, decreasing the
degradation rate at a given Mw [41].
2.4.2 Preparation of PLGA Microparticles
Microspheres are spherical, drug containing particles, typically between 1–100 µm in diam-
eter; millicylinders are cylindrical, drug containing particles, typically between 0.5–2 mm in
diameter and 1–10 mm in length. Several methods have been developed to encapsulate drugs
into polymer microspheres. A successful encapsulation method produces microspheres with
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a) unaltered structure and activity of the encapsulated drug, b) high drug encapsulation effi-
ciency and microsphere yield, c) reproducible physical characteristics and release profiles,
and d) low residual solvent. Three of the most commonly used methods to produce micro-
spheres are emulsion-solvent evaporation, coacervation, and spray drying. Millicylinders are
produced using and extrusion process. Since emulsion-solvent evaporation is typically used
to prepare microspheres at the bench scale, it will be described in detail below, followed by
a brief description of extrusion, coacervation and spray-drying techniques.
The emulsion-solvent evaporation methods can be subdivided into four categories:
oil-in-water (O/W), (water-in-oil)-in-water (W/O/W), (solid-in-oil)-in-water (S/O/W), and
oil-in-oil (O/O). The suitability of each technique is determined by the solubility and stability
of the drug to be encapsulated. In the O/W method, the polymer and drug are dissolved in a
volatile, water-immiscible organic solvent and emulsified into and aqueous phase containing
surfactant. As the volatile organic solvent diffuses into the continuous phase and evaporates,
the microspheres harden and precipitate. This is commonly referred to as in-liquid drying.
The O/W method is only useful for hydrophobic drugs, since they can dissolve in the organic
solvent and wont leach into the aqueous continuous phase.
Water soluble drugs, such as peptides and proteins must be encapsulated using a multiple
emulsion technique. The W/O/W is the most commonly used multiple emulsion method to
encapsulate proteins. First, a buffered protein solution is emulsified into a volatile, water-
immiscible organic solvent containing polymer using a sonicator, homogenizer, or vortex
(W/O). The resulting primary emulsion is then added to a second aqueous phase containing
surfactant and a second emulsion is formed (W/O/W). The organic solvent then diffuses into
the continuous aqueous phase and is evaporated, precipitating the microspheres. Finally, the
microspheres are filtered, rinsed, and lyophilized.
The S/O/W method is similar to the O/W method, except the former consists of
lyophilized drug/excipient particles dispersed into a polymer containing organic phase,
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rather than a dissolved hydrophobic drug. The S/O/W method may be preferred when
structural perturbations occurring during the formation of the primary emulsion using the
W/O/W technique lead to significant protein inactivation.
In the O/O method, the drug and polymer are first dispersed and dissolved, respectively,
in an organic solvent, typically acetonitrile. The dispersion is then emulsified into an oil
phase containing surfactant, typically a Span surfactant in cottonseed oil. After extraction of
the organic solvent, the microspheres are washed with a solvent such as petroleum ether.
Microspheres prepared by the O/O method are typically larger than those prepared by
the W/O/W due to the coalescence of particles during the long evaporation process [42],
although lower interfacial tension between the two oil phases relative to the O/W interface
can result in smaller particles if evaporation is sufficiently rapid [43]. The O/O technique is
useful when use of water is undesirable due to stability issues or when low encapsulation
efficiency is obtained using W/O/W due to the leaching of a highly water soluble drug to the
aqueous hardening bath [43].
For millicylinder preparation, a suspension of sieved drug/excipient particles (<90 µm)
in acetone-PLGA solution (50% wt/wt) is loaded in a syringe and extruded into silicone
rubber tubing (0.8 mm i.d.) at approximately 0.1 ml/min [44]. The solvent-extruded suspen-
sion is then dried at room temperature for 24 hours and then under vacuum at 37–45◦C for
another 24 hours.
Coacervation, or phase separation, is a process where microspheres are precipitated by
adding a cosolvent to decrease the solubility of the polymer. Similar to the O/O method,
the drug and polymer are first dispersed and dissolved, respectively, in an organic solvent.
Next, a miscible cosolvent is added, resulting in phase separation of microspheres into
a coacervate phase. There are two main disadvantages of the coacervation method: a)
it typically produces agglomerated particles, since no surfactant is used to stabilize the
emulsion and b) it requires large amounts of solvents that are difficult to remove from the
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microspheres after drying [45].
In spray drying methods, lyophilized peptide or protein is dispersed in a polymer con-
taining solvent and atomized by a nozzle into fine particles. These particles can then sprayed
into heated air to remove the solvent [45] or into frozen ethanol (the extraction agent) with
liquid nitrogen overlaid [46]. Spray drying involves milder conditions that double emulsion
solvent evaporation techniques, is rapid, easy to scale up, and can be done aseptically
[47]. For these reasons, spray drying is often used for industrial scale manufacturing of
microspheres.
2.4.3 Polypeptide Instabilities in PLGA Controlled Release Systems
Protein instabilities fall under two major categories: physical and chemical. Physical and
chemical instablilities often result in a protein that is inactive, immunogenic, or toxic. Physi-
cal instabilities such as denaturation, aggregation, adsorption, or precipitation result in a
change of conformation or state. On the other hand, chemical instabilities such as hydrolysis,
deamidation, oxidation, disulfide exchange, cross-linking, or racemization result in a change
in the amino acid composition of a peptide or protein. Physical and chemical instabilities
are not mutually exclusive—a physical instability may lead to a chemical instability and
vice versa. A common example is covalent aggregation resulting from β -elimination or
disulfide interchange. Detailed descriptions of physical and chemical instabilities have been
reviewed elsewhere [48, 49, 50, 51, 52, 53, 54, 55] and are summarized in Table 2.1.
Incomplete release of native protein from PLGA microparticles is often a result of
physical and chemical instabilities. Almost all reported cases of incomplete release of native
protein from PLGA microspheres have been a result of physical instabilities, for example
aggregation incurred during manufacture [57, 58, 59] or as a result of low microclimate
pH (µpH) [60, 61]. Recently, methods have been developed to stabilize proteins against
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Table 2.1 Mechanisms and characterization methods of physical and chemical instabilities of
peptides and proteins [48, 51, 56].
Inactivation
Process Mechanism Characterization Method
Chemical Instabilities
Hydrolysis
Acid-catalyzed peptide bond cleavage at
X-Asp or Asp-X linkage especially for
Asp-Gly and Asp-Pro.
Determine MW by SDS-PAGE or
MS.
Oxidation
Oxidation occurs typically at Met, Trp, His,
Cys, and Tyr in the presence of oxidants
such as air, peroxides, metal ions and
DMSO.
Monitor MS changes by LC-MS,
amino acid analysis, RP-HPLC, or
by using chemical reactions, e.g.
CNBr reacts with nonoxidized Met
only.
Deamidation
Acid- or base-catalyzed hydrolysis of Asn
residues to cleave the amide bond of the
side chain via a cyclic imide intermediate.
Occurs most often at Asn-Gly linkages.
Can also occur at Gln but at a much slower
rate.
Measure the amount of ammonia





Base-catalyzed reaction of cystein residues
with Lys and thiocystein to generate
dehydroalanine, lysinoAla, and thols.
Determine free thiol groups by
Ellmans reagent, dehydroalanine by
amino acid analysis, and measure
isoelectric point change.
Racemization L-amino acids transform to D-enantiomers,especially for Asp.
Monitor conformational changes by
fluorescence, circular dichroism, or
amino acid analysis using chiral
chromatography.
Acylation
Nucleophilic primary amines interact with
solid PLGA and/or PLGA degradation
products, resluting in the addition of





noncovalent forces or covalent linkage.
Severe aggregation can cause precipitation.
Covalent aggregation results from




Measure CD and fluorescence
spectra or determine secondary
structure by FTIR.
Denaturation
Disruption of secondary structure by
denaturants such as extremes of pH, heat,
organic solvents, or detergents.
Characterize the aggregates by
SDS-PAGE or size exclusion
chromatography. Dissolve
precipitates in denaturing solvents
such as 6 M GuHCl or urea.
Adsorption
Adhesion of proteins to surfaces by surface
interaction due to relatively high interfacial
activity of proteins.
Detect structural changes using
FTIR, CD, or fluorescence spectra.
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physical instabilities during manufacture and release, for example by using the S/O/W
encapsulation method [57, 58, 59] or coencapsulating a basic excipient [60, 61]. As large
structural perturbations resulting from physical instabilities can now be circumvented for
many proteins, there is now a need to investigate the magnitude of chemical instabilities
within polymer microspheres. Herein, instabilities during manufacture, storage and release
will be discussed with an emphasis of physical instability, followed by a brief overview of
two important chemical degradation reactions: deamidation and oxidation.
Physical Instabilities During Manufacture
During W/O/W encapsulation, proteins are exposed to conditions that are known to cause
denaturing and aggregation, namely high shear [62, 63], elevated temperature, exposure to
the air/liquid interface, organic solvents and the O/W interface [59, 64, 65]. Furthermore,
stabilizing excipients that have solubility in the oil phase may diffuse into the polymer
solution or be lost to the continuous aqueous phase. Higher energy emulsification methods,
which may be necessary to achieve smaller particle sizes, are more detrimental to proteins
than lower energy methods (e.g. sonicator > homogenizer > vortexer). High viscosity
polymer solutions require more energy during emulsification and dissipate more energy
as heat, and should be avoided. The addition of an aqueous protein solution to an organic
solvent can lead to denaturing of proteins [59, 66]. Proteins, which are surface active, can
diffuse to the O/W interface and aggregate non-covalently or covalently upon exposure of
the hydrophobic core and subsequent disulfide scrambling.
For proteins where aggregation at O/W interfaces is a major instability, such as ribonu-
clease A (RNase A) [59], alternative encapsulation procedures, such as the S/O/W method
may be necessary. The S/O/W encapsulation method decreases the stresses from exposure to
the O/W interface as well as shear and high temperature during primary emulsification. The
conformation of lyophilized protein is locked when it is added to organic solvent, because
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the lack of lubricating water [65]. Therefore, retaining the native state during lyophilization
is crucial for successful encapsulation using the S/O/W method. Decreased mobility of pro-
teins upon dehydration stabilizes them against shear and elevated temperature encountered
during emulsification. However, upon forming the O/W emulsion, proteins dispersed in the
oil phase are rehydrated, sometimes unintentionally forming a W/O/W emulsion [67].
Physical and Chemical Instabilities During Storage
Proteins and microspheres are often lyophilized prior to long term storage. The removal
(and uptake) of water can destabilize proteins if excipients are not present to replace the
hydrogen bonds [68]. Although degradation reactions occur at a much faster rate in solution,
proteins in the solid state are not necessarily stable [53, 69]. Temperature, residual moisture,
and interactions between protein, polymer, or excipients all threaten stability during storage
in dehydrated polymer microparticles. The storage temperature should be maintained well
below the protein Tg to minimize molecular mobility and chemical degradation reactions
[70]. Residual moisture also increases molecular mobility, acts as a reactant or mobile
phase for reactants in several degradation reactions, and lowers Tg and can thus compromise
chemical stability of peptides and proteins encapsulated within polymeric microparticles
[52]. Furthermore, residual moisture can prematurely degrade the polymer, altering the
release profile and lowering pH, which in turn may accelerate deleterious reactions [71]. The
lowered pH may also hydrolyze non-reducing sugars used as excipients, resulting in reducing
sugars that may covalently bind to lysine residues [72]. Residual moisture also affects aggre-
gation of polypeptides via thiol-disulfide exchange [73, 74, 75] or formaldehyde-mediated
cross-linking [76, 77].
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Physical Instabilities During Release
During release from polymer microparticles, polypeptides are exposed to many stresses that
can compromise their physical and chemical stability. These include rehydration, exposure
to soluble oligomers, low µpH, interactions with the polymer, loss of stabilizing excipients,
and physiological temperature.
Upon incubation in an aqueous release medium, water will diffuse into microspheres,
causing them to swell. The rate of water uptake is dependent on the hydrophilicity of the
polymer, microsphere porosity, and loading of drug and excipients. The uptake of water
can result in moisture-induced aggregation, as previously mentioned. Moisture-induced
aggregation occurs within a window of water content: at low water contents, an insufficient
amount of water is present to act as a lubricant (e.g. insufficient conformational flexibil-
ity), to participate in deleterious processes, or to facilitate the diffusion of reactants [73].
At higher water concentrations, protein particles are diluted and are sufficiently hydrated
properly refold [73].
Polymer degradation and the formation and enlargement of pores commences imme-
diately upon water uptake. PLGA degrades to lower molecular weight oligomers and
eventually LA and GA via a combination of chain end and bulk ester bond hydrolysis
[78, 79]. As degradation proceeds, the molecular weight distribution decreases and the
amount of acidic chain-ends increases. Oligomers up to 7–10 monomer units, depending on
polymer composition, pH, etc., are soluble in water and diffuse into the aqueous pores. This
increases the osmotic pressure inside the microsphere pores, resulting in additional water
uptake [80]. Water soluble oligomers may also participate in a stabilizing or destabilizing
co-solvent interaction with encapsulated proteins [81].
Acids generated during degradation autocatalyze PLGA hydrolysis [82]. Because of an
increased resistance to oligomer diffusion at the center of microspheres, acidic degradation
products accumulate resulting in heterogeneous degradation and µpH [83]. Even a dilute
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lactic acid solution has substantially low pH that is detrimental to protein physical stability.
For example the pH of 5% (w/w) lactic acid is 2.0 [84]. The extent of accumulation of acidic
degradation products depends on the rate of formation and release of soluble oligomers, wa-
ter uptake, and the presence of buffering salts [85]. The accumulation of acidic degradation
products can be substantial in many microsphere formulations and is affected by the radial
distance of a pore from the center as well as microsphere properties such as size, porosity,
and drug loading. Using confocal microscopy, Fu et al. have shown that the µpH of 40 µm
microspheres increases from 1.5 in the center to 3.5 at the surface [86].
Many proteins denature at low pH, providing a driving force for non-covalent aggre-
gation via non-covalent interactions. For example, simulations of the PLGA microclimate
have shown that bovine serum albumin (BSA) aggregates non-covalently and undergoes
peptide bond hydrolysis at pH < 3 [60]. BSA undergoes a conformational transition from
the partially denatured, F to the fully denatured E isoform at pH 2.7 [87]. Poorly water
soluble bases, such as Mg(OH)2 or MgCO3, can be added to neutralize the µpH and prevent
acid-induced denaturing, aggregation, and peptide bond hydrolysis [60].
Adsorption of polypeptides can also affect their stability. Adsorption often results in
the exposure of the hydrophobic interior of proteins and can often lead to the formation
of insoluble aggregates or irreversible conformational changes [88]. Even when adsorp-
tion is reversible, it may accelerate other deleterious reactions by exposing previously
buried residues or increasing side chain mobility. The double emulsion solvent evaporation
technique produces highly porous microspheres with a large surface area for adsorption.
Furthermore, as microspheres degrade and erode, the specific surface area may increase
substantially [89]. Therefore, adsorption may become a greater factor in drug release and
stability at later incubation times. Adsorption can be minimized by the addition of other
proteins, such as BSA, or surfactants, such as SDS, that competitively interact with the
polymer [89]. Pegylation has also been reported to decrease the adsorption of octreotide
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and lysozyme to blank PLGA particles and microspheres, respectively [90, 91]. It is unclear,
however, whether the loss of soluble protein was due to adsorption or a decrease in pH upon
microsphere degradation.
Chemical Instabilities During Release
Among irreversible chemical changes to peptides and proteins, deamidation and oxidation
reactions are among the most common [92], and have been reported for human growth
hormone encapsulated in PLGA microspheres [93]. In the presence of PLGA, acylation has
also been reported to occur [94].
Crystal structures of deamidated lysozyme [95] and ribonuclease A [96] show that
deamidation induced isoaspartate formation introduces a 90◦ bend to the polypeptide chain.
Such alterations can result in decreased bioactivity if the labile Asn is near an active site.
While deamidation does not affect the bioactivity of all proteins, the bioactivity of many
proteins is affected by deamidation [97, 98, 99, 100, 101, 102, 103]. For examples, the
bioactivity of rhGH, insulin, and IL-1α and -2 are not significantly affected by deamidation,
while calmodulin, EGF, growth hormone releasing factor, parathyroid hormone, triosephos-
phate isomerase (TPI), and RNase A all show decreased bioactivity upon deamidation
[98]. IsoAsp formation may serve as a trigger for proteolytic degradation of some proteins,
such as serine hydroxymethyltransferase [104] and TPI [105], or significantly increase
autoimmunogenicity of others, for example cytochrome C peptide fragments [106]. The
presence of isoaspartyl peptides have also been observed as a major component of the
amyloid-containing brain plaques of patients with Alzheimers disease [107].
Oxidation or acylation may affect bioactivity of peptides and proteins in a similar
manner– if a labile residue is near an active site, loss of activity may occur. Toxicity may
also occur as a result of oxidation or acylation. For these reasons, chemical instabilities of
therapeutic biomolecules may raise concerns of regulatory agencies, regardless of whether
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the proteins bioactivity is affected. In the next section, we will review literature reports of
peptide acylation, the reaction that is the focus of this dissertation. At this time, there have
been no reports of the acylation of large proteins.
Acylation with PLGA
PLGA can interact with nucleophiles (other than water), such as an amine-containing drug
(peptide), resulting in an acylation reaction between the drug and the polymer. This re-
action involves the nucleophilic attack by the drug on the lactate- or glycolate-endgroup,
followed by hydrolysis [94]. Acylation is believed to only occur with oligomers and not
with monomeric lactic or glycolic acid [108, 109]. The rate of this reaction is a function
of pH, the reactivity of the polymer (e.g. MW and LA:GA ratio), the nucleophilicity of the
drug, and the concentration of water, drug, and polymer [108].
Several authors have investigated the effect of pH and lactic acid concentration on pep-
tide acylation in lactic acid solutions [109, 110, 111]. However, increasing the concentration
of lactic acid in solution results in a decreased pH as well a shift in the equilibrium between
free and esterified lactic acid to higher amounts of oligomers [109, 110]. For example, in
a study by Lucke and Gopferich [109], as the concentration of lactic acid increased from
1 to 50%, the pH decreased from 2.3 to 1.0 and the oligomer content increased from 0.1
to 14%. Because of this, one is unable to discriminate between the effect of pH and the
equilibrium of free and esterified lactic acid in solutions at different pH values on peptide
acylation. Nevertheless, reactions between peptides in lactic acid solutions have shown that
the rate of acylation increases with lactic acid concentration as well as decreased pH. As
the pH of 42.5% lactic acid solutions containing octreotide increased from 2.2 to 4.2, the
amount of octreotide degradation products decrease, with none detected at pH 6.1 [111].
Murty et al. studied the effect of polymer composition, polymer MW , and release
medium buffer on the acylation of octreotide encapsulated in PLGA microspheres [112].
In both acetate and PBS, acylation decreases with increasing lactide composition (PLGA
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50:50 > PLGA 85:15 > PLA 100) as well as decreasing MW (high MW PLGA 50:50 > low
MW PLGA 50:50). The decreased reactivity of octreotide with lactic acid units relative to
glycolic acid units is hypothesized to result from steric hindrance of the additional methyl
group on the α-carbon. The authors suggest the increased reactivity of octreotide in high
MW PLGA may be a result of the longer exposure time of the peptide inside the microsphere
due to the substantial decrease in the initial burst relative to the low MW PLGA (50% release
in acetate at 1 day vs. 21 days, respectively). However, the former suggestion is refuted by
the PBS release data, where the amount of acylation is similar after the 21 day lag time in
high MW microspheres and after the 1 day burst release in low MW microspheres.
Acylation was also significantly enhanced when the microspheres were incubated in
PBS, relative to acetate buffer, possibly due to the plasticization of the polymer by acetic
acid, facilitating the transport of reactive oligomers out of the microspheres. Further studies
are required to elucidate the effects of release media buffer type and pH on the transport of
buffer salts, oligomers, and peptide and their effect on the polymer degradation and acylation
rates.
Later, Murty et al. investigated the effect of water uptake on octreotide acylation in
PLGA 85:15 and PLA microspheres [111]. Octreotide in microspheres that were incubated
under anhydrous conditions did not undergo acylation. The authors surmised that because
of water uptake, the hydrolytic cleavage of the polymeric backbone created an acidic mi-
croenvironment to facilitate the covalent coupling of peptide with polymer. However, they
could not discriminate between the effects of water as a plasticizer, solvent medium, or a
direct participant in the acylation reaction.
Structural effects, such as differences in pKa’s, net charge, and hydrophobicity, also
play a role in the rate and extent of peptide acylation. Octreotide contains two reactive
amino groups, one on the n-terminus and another on the Lys side chain. Mass specrometry
analysis on octreotide degradation products showed that the n-terminus is more likely to be
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acylated than the lysine side-chain [112]. This is because the pKa of the lysine is higher than
the n-terminus, so at physiological pH a larger proportion of the n-terminal amine groups
should be in the more nucleophilic deprotonated form. Lucke et al. performed a release
study to compare acylation between atrial natriuretic peptide (ANP) and sCT in PLA and
PLGA microspheres [94]. After 28 weeks, 50% of the ANP was released vs. 4% of the sCT.
They found that the rate of acylation is substantially higher for ANP than sCT (60% vs 7%
in PLA, respectively), demonstrating the unknown role structural effects play in peptide
reactivity.
Na et al. studied the effect of PEGylation on octreotide sorption to free acid-endgroup
and end-capped PLGA 50:50 subsequent acylation in phosphate buffer (0.1 M, pH = 7.4)
[90]. Removing the reactive n-terminal amine by PEGylation was shown to completely
eliminate the acylation of octreotide, suggesting that acid end-groups of PLGA are involved
in interactions with amino groups of octreotide. PEGylation at lysine also substantially
reduced acylation, possibly by reducing the ionic interaction between the peptide and the
polymer or shielding the n-terminus from reacting.
Strategies to Stabilize Peptides and Proteins in PLGA Controlled Release Systems
Peptides and proteins encapsulated within PLGA controlled release systems are exposed
to many destabilizing stresses during manufacture, storage, and release that may result
in incomplete release or release with reduced biological activity. A rational stabilization
approach is necessary when formulating a therapeutic polypeptide delivery system in order
to achieve complete release of active drug. Volkin and Klibanov have suggested a paradigm
for rational stabilization of proteins [113], which has been the paradigm utilized in this re-
search: 1) determine the major sources of inactivation, either directly or through simulation;
2) elucidate the molecular mechanisms of inactivation; and 3) devise methods to prevent,
bypass, or minimize the specific mechanisms.
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Several general approaches have been utilized to stabilize proteins by increasing their
intrinsic stability [51]. These include the use of stabilizing excipients, chemical modification,
and reduced mobility [113]. Excipients such as salts, sugars, and polyols stabilize proteins
by preferentially hydrating the native state [81]. Additionally, excipients can react with
species involved in deleterious reactions, for example ROS scavengers, such as thiourea or an
oxidizing peptide, to minimize oxidation or non-oxidizing metals that bind to metal-binding
sites, reducing MCO. Chemical modifications such as pegylation can physically stabilize
peptides and proteins [91, 114]. Site-directed mutagenesis can be used to chemically sta-
bilize polypeptides, by removing a labile residue, such as Asn or Asp [115]. Peptides and
proteins in the solid state are more stable than in solution because of the decreased mobility
of side chains and extended loops. The mobility of drugs can be reduced by loading them
above their solubility, cross-linking with glutaraldehyde, or intentionally precipitating them
(e.g. protein preicpitation with zinc).
Several methods to minimize peptide acylation within PLGA microparticles have been
proposed, based on the studies mentioned above, including: (a) increasing the microclimate
pH from 2 to 6 [94, 109, 111], (b) reducing polymer hydrolysis rate by encapsulating with
PLGAs of high lactic:glycolic ratio [94, 112], (c) facilitating the release of water soluble
oligomers (for example by using PEG as a porosigen) [94], and (d) shielding the reactive




To study the acylation of peptides in PLGA, we selected a model system comprised of PLGA
particles or films exposed to solutions of the model peptides, representing the aqueous
pore/polymer phase interface and microenvironment within microspheres or other implant
devices after injection and subsequent hydration.
3.1 Selection of polymers for investigation
The Boehringer-Ingelheim Resomer R© family of PLGA 50:50 polymers were primarily used
for this research. The Resomer R© PLGAs were chosen to conveniently compare the effect of
molecular-weight and capping of the carboxylic acid end-groups within a group of polymers
with similar manufacturing methods and in order to validate our results against previously
published work, which also primarily use Resomer R© PLGAs. Table 3.1 summarizes several
characteristics supplied from the manufacturer of the PLGAs typically studied that are
particularly relevant to peptide acylation, namely the composition of the PLGA end-group,
PLGA molecular-weight, number of acid end-groups, and dry glass transition temperature
reported by the manufacturer. Upon incubation in water, PLGA 50:50 rapidly absorbs water,
plasticizing the polymer and depressing Tg by up to 18◦C [39, 40]. The Tg of RG503H was
previously shown to be depressed from 45.5 GA31.7◦C within 1h after incubation in water at
37◦C [40] (see aslo Section 2.4.1).
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Table 3.1 Characteristics of Boehringer-Ingelheim Resomer R© PLGAs. Molecular weight polydis-



















RG 502H Yes 6.7 10.4 185 42-46
RG 503H Yes 20.9 5.3 95 44-48
RG 504H Yes 31.3 3.0 53 46-50
RG 502 No 6.9 <1.0 <17 42-46
RG 503 No 25.3 <1.0 <17 44-48
The PLGA RG502H was chosen as the ’base-case’ polymer due to its high acid-content
and low molecular weight, which were hypothesized to increase sorption and acylation as
well as provide sustained release of peptides. All references to ’PLGA’ in Chapters 6-7 refer
to RG502H unless otherwise specified. It should be noted that due to its high number of
acid end-groups, high fraction of soluble oligomers [116], and very low molecular-weight,
this polymer could be considered an ’oligomer’ with properties intermediate between higher
molecular-weight ’polymers’ and water soluble oligomers.
3.1.1 Characterization of PLGA particles
RG502H particles, as received from the manufacturer, had a very rough surface morphology
with many pits and crevices (Figure 3.1(a)). The general surface morphology was not sig-
nificantly affected by 24 hour incubation at typical experimental conditions (0.1M HEPES
buffer, pH 7.4, 37◦C, Figure 3.1(b)), indicating that peptide entrapment resulting from
polymer rearrangements is unlikely. Multipoint Brunauer-Emmett-Teller (BET) analysis of
N2 sorption to RG502H particles shows a surface area of 4.6 m2/g (Figure 3.2).
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A 2c 2 0.81 2000 15 150 60
B 7c 7 0.82 1800 15 150 60
C 13d 12 0.87 1600 15 150 60
D 24c 17 0.87 1300 20 200 80
E 40d 22 0.89 1000 20 250 100
a Volume used for 4cm diameter films.
b Volume used for 2.5cm diameter films.
c Estimated using PLGA density and mass of PLGA added.
d Measured by SEM.
3.1.2 PLGA film preparation and characterization
PLGA films of varying thicknesses were prepared for various studies of peptide sorption
to PLGA. These films have been labelled A-E, as indicated in Table 3.2. To prepare the
films, solutions of 2, 7, 12, 17, and 22 wt% PLGA 50/50 in acetone were added to a 4
or 2.5cm diameter glass microscope cover slide placed within a spin-coater (SCS G3-8,
Indianapolis, IN). Spin-coating of the PLGA solutions were done at the conditions shown
in Table 3.2. Following spin-coating, nascent PLGA films were placed in a Petri-dish with
tight-fit lid (Beckton-Dickinson, Franklin Lakes, NJ) and dried for 48 hr at room temperature
and pressure followed by 24 hr in a vacuum oven at 25◦C.
The thickness and morphology of PLGA films were analyzed with a scanning electron
microscope (Amray 1910). PLGA films appear to have a very smooth surface with even
thickness throughout. The thickness of PLGA film E was determined to be ∼40µm, as
shown in Figure 3.3. The density of PLGA films was 1 g/cm3, based on the calculated
mass of PLGA added, determined using the density of PLGA solutions (Table 3.2). The
thickness of hydrated PLGA film C was also analyzed by SEM. Although the presence of
octreotide induces some roughness on the surface (see Figure 7.3), the thickness of this film
was ∼13µm, corresponding to exactly the same PLGA density of 1 g/cm3. The thicknesses
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of other films were estimated assuming constant PLGA density.
The zeta potential of PLGA Film B slides (9 x 18 mm) were evaluated using the SurPASS
Electrokinetic Analyzer (Anton Paar USA, Ashland, VA). The samples were measured using
the adjustable gap cell, containing two sample slides coated with PLGA, with a 1 mM
potassium chloride electrolyte solution, pH 7.5. The measurements were able to differentiate
between the surface properties of the three slide samples. Each sample was first rinsed
at a maximum pressure of 300.0 mbar for 180 seconds before the streaming current was
measured at a target pressure of 300.0 mbar for 20 seconds.
The zeta potential, ζ , was calculated to be -70 mV, according to the following equation









where dIdP is the slope of the streaming current vs. the differential current, η is the electrolyte
viscosity, ε is the dielectric constant of the electrolyte, ε0 is the permittivity of free space, L
is the length of the streaming channel, and A is the cross-section of the streaming channel.
3.2 Model peptides
The model peptides used in this research included octreotide as the primary acylating model
peptide, and leuprolide as a secondary non-acylating peptide for comparison of sorption.
Both of these peptides have successful PLGA controlled release products on the market
(See Section 2.4). Octreotide is a somatostatin analogue, used pharmacologically to treat
acromegaly, that is a cyclic octapeptide with a molecular weight of 1019.3 g/mol, containing
an intramolecular disulfide and two amino-groups— one at the n-terminus (pKa ∼7.8)
and one on the lysine side chain (pKa ∼10.1) [117]— that are potential acylation sites.
29
Leuprolide is a gonadotropin-releasing hormone agonist, used pharmacologically to treat
prostate cancer, that is a linear nonapeptide with a molecular weight of 1210. It does not
contain any acylating amino-groups, but has an ionizable histidine imidazole (pKa ∼6.0)
[117].
Greater than 99% of native octreotide was recovered after 24 hr incubation at 37◦C in all
buffers typically used in these studies (e.g. HEPES, acetate, and phosphate), except at 100
mM phosphate concentration and PBST, where >85% of native octreotide was recovered.
3.3 General Methodology
In this thesis, the sorption of model peptides and other divalent cations to PLGA is investi-
gated. To assess the sorption, aqueous solutions of peptides were incubated in the presence
of polymer particles or films. Peptide sorption to PLGA was determined primarily using the
difference method for sorption to PLGA particles and by recovery from the polymer via-two
phase extraction for sorption to PLGA films. The concentration of peptide in solutions was
measured by UV spectrophotometry after reverse phase-HPLC.
Validation studies were performed to ensure that the loss of peptide from solution did
not result from sorption to the sample container or other degradation reactions, and that
the presence of other excipients (e.g. divalent cations) did not affect the RP-HPLC/UV
detection. (See Sections 4.2.8 and 4.2.2, respectively, for more details.) A mass balance
on octreotide was also performed, showing that all of the octreotide is recoverable via
two-phase extraction after 1 hr sorption (see Section 4.2.8).
Other auxiliary studies were also performed to analyze the peptide/cation/PLGA system,
such as analysis of peptide-PLGA solubility, surface characterization by XPS, zeta-potential
measurements.
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3.4 Uncertainty and Error Analysis
Uncertainties in reported values are presented as standard errors of the mean (s.e.m.) for an
experimental sample size of 3, unless otherwise noted. The uncertainty of several measure-
ments were propagated into the values of the s.e.m. These include uncertainties of: balance,
pipette, HPLC injector, and standard curves for sorption studies using the difference method.
In several cases, the s.e.m. values were smaller than the dimensions of the data point symbol
and were omitted for clarity. In tables, the values of the s.e.m. values are shown except in
cases where they are less than the order of the last significant digit reported.
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Figure 3.1 Boehringer-Ingelheim Resomer R© RG502H particles before (top) and after (bottom)
24 hour inucbation at 37◦C in 0.1M HEPES buffer, pH 7.4
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Figure 3.2 Surface area determination via multi-point BET analysis of N2 sorption to RG502H
particles.
Figure 3.3 Scanning electron micrograph of a cross section of a PLGA 50:50 film prepared
according to E conditions (see Table 3.2) on a glass substrate.
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Figure 3.4 Structure of octreotide, D-Phe-c(Cys-Phe-D-Trp-Lys-Thr-Cys)-Thr-ol (left). Structure
of leuprolide, pGlu-His-Trp-Ser-Tyr-D-Leu-Leu-Arg-Pro-NHEt (right).
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Chapter 4
A new class of inhibitors of peptide
sorption and acylation in PLGA
4.1 Introduction
Injectable biodegradable microspheres and implants control the release of peptide or protein
drugs over the course of weeks to months, providing a distinct advantage over daily injec-
tions in terms of patient acceptability and compliance. The PLGA family of copolymers of
lactic and glycolic acids is one of the few biodegradable polymers used in US FDA approved
pharmaceutical products or medical devices [118], and is widely used in commercially avail-
able controlled release peptide delivery systems, including the Lupron Depot R© (leuprolide
acetate), Sandostatin LAR R© (octreotide acetate), and Zoladex R© implant (goserelin acetate).
A very significant challenge in the development of controlled release PLGA systems
is the instability of peptides and proteins. For larger protein molecules numerous physical
and chemical pathways of instability have been extensively reviewed [51, 71, 119, 120].
Acylation was postulated [51] and later proven as a pathway of instability for peptides encap-
sulated in PLGA implants [94]. Nucleophilic primary amines, such as from the N-terminus
and lysine side chain, can interact with solid PLGA and/or PLGA degradation products
to form acylated peptide adducts [108]. Peptide acylation may potentially result in loss of
activity [121], a change of receptor specificity, or immunogenicity (see [94] and citations
therein). For the important, clinically used octreotide, acylation has been shown to occur
35
in both linear PLGA and glucose-star PLGA copolymers [111, 112], and a mechanism
has been proposed to involve an ionic interaction between a protonated amine and the
carboxylate PLGA end-group, followed by a nucleophilic attack of another nucleophilic
amine on the lactic or glycolic carbonyl carbon and subsequent polymer hydrolysis [90].
Several methods to minimize acylation within PLGA microparticles have been proposed,
including: (a) increasing the microclimate pH from 2 to 6 [94, 109, 111], (b) reducing poly-
mer hydrolysis rate by encapsulating with PLGAs of high lactic:glycolic ratio [94, 112], (c)
facilitating the release of water soluble oligomers (for example by using PEG as a porosigen)
[94], and (d) shielding the reactive amino-group on the peptide by PEGylation [90]. Unfor-
tunately, these methods either: do not strongly inhibit acylation, limit formulation options,
or involve chemically modifying the drug molecule. Additional approaches, particularly
the use of additives, are needed to optimize PLGA delivery of peptides susceptible to this
reaction.
Na and Deluca [90] have shown that the interaction of octreotide with PLGA was attenu-
ated when the polymer was end-capped and when octreotide was PEGylated, resulting in an
inhibition of acylation. This important finding strongly suggests a critical precursor role
of the ionic interaction between dicationic octreotide and the carboxylic acid end-groups
of PLGA in acylation. This peptide-polymer interaction is the basis for our first effort to
identify new acylation inhibitors.
PEGylating polypeptide therapeutics is an attractive option for molecules that would
benefit from improved physical stability, resistance to proteases, reduced immunogenicity,
or increased half-life. In some cases, PEGylation may be a useful strategy for extending
an existing products patent-life by applying for regulatory approval of the new chemical
entity. Unfortunately, there are many documented cases where PEGylation has resulted in a
substantial decrease in receptor affinity [122] or may not be a feasible strategy because of
financial concerns with gaining approval of a new drug entity.
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The interaction of cations in the diffuse side of electric double layers of negatively
charged surfaces is well documented [123]. Similarly, the binding mechanism of diva-
lent cations to surfaces such as emulsion droplets [124] and phospholipid membranes
[125, 126, 127, 128] has been the topic of extensive research. The specific interaction
of divalent cations with biological membranes is essential for several cellular processes,
including endo- and exo-cytosis, signal transduction, transport of molecules, and binding of
proteins. This body of work motivated us to investigate the effect of water-soluble inorganic
divalent cationic salts on the interaction between octreotide and PLGA. Indeed, we found for
certain cations, such as Ca2+ and Mn2+, which are significantly present in living systems,
a very strong inhibition of both peptide sorption to PLGA and peptide acylation using
octreotide as a model peptide.
4.2 Materials and Methods
4.2.1 Materials
Octreotide acetate was obtained from Novartis (Basel, Switzerland). PLGA 50:50
(Resomer R© RG502H) was purchased from Boehringer-Ingelheim GmbH (Ingelheim, Ger-
many). Poly(lactide) (i.v. 0.1-0.2 dL/g) and poly(ethyleneimine) (Mw ∼25,000 Da) were
purchased from Polysciences, Inc. (Warrington, PA). Poly(arginine) (Mw ∼10,000 Da),
(Hydroxyethyl)-piperazine-(ethanesulfonic acid) (HEPES), calcium chloride (CaCl2), mag-
nesium chloride (MgCl2), manganese chloride (MnCl2), and sodium chloride (NaCl) were
purchased from Sigma-Aldrich Chemical Co. (St. Louis, MO). Nickel chloride (NiCl2) and
strontium chloride (SrCl2) were purchased from Fisher Scientific. Standard solutions for
inductively coupled plasma-optical emission spectroscopy (ICP-OES) were purchased from
GFS Chemicals (Columbus, OH). All other reagents used were of analytical grade or purer
and purchased from commercial suppliers.
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4.2.2 Analysis of octreotide by HPLC
The concentration of native and acylated octreotide was determined by RP-HPLC and
the octreotide degradation products were identified as acylated octreotide by HPLC-MS,
similarly as described by Murty et al. [112]. Injection volumes of 20 µL were loaded onto a
Nova Pak C-18 column (3.9 x 150 mm, Waters) for RP-HPLC (Waters Alliance R©) analysis
using UV detection (280 nm). Solvent A was 0.1% TFA in acetonitrile and Solvent B was
0.1% TFA in water. A linear gradient of 25 to 35% A in 10 min, with a flowrate of 1.0
mL/min was used.
Solutions of octreotide (0.9 mM) before and after the addition of CaCl2 and MnCl2 (50
mM) were analyzed by HPLC after 24 hr incubation to validate that the divalent cations do
not interfere with the HPLC analysis or degrade octreotide. The addition of CaCl2 or MnCl2
did not affect the concentration of octreotide detected (data not shown).
4.2.3 Analysis of octreotide by HPLC-MS
The formation of acylated octreotide was verified by HPLC-MS, where a linear gradient of
15 to 45% A in 30 min was used, with a flowrate of 1.0 mL/min, followed by infusion into
an electrospray ionization mass spectrometer with ion-trap detection in positive ion mode
(ThermoFinnigan Surveyor HPLC and LCQ MS, San Jose, CA). Acylated peak identifica-
tion was performed against a reference sample that was previously analyzed by HPLC-MS,
shown in Figure 4.1(a). The reference sample was prepared from octreotide, which was
acylated using a PLGA-based polymer. Note that the concentration of the reference sample
was high causing detector saturation and the appearance of two parent octreotide peaks.
Figure 4.1(b) shows a sample HPLC chromatogram of octreotide incubated with PLGA
for 28 days (see Figure 4.6) with the corresponding peak assignments obtained from the
reference acylated sample in Figure 4.1(a). Table 4.1 gives the Mw and identification of the
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Table 4.1 LC-MS identification octreotide acylation products.












acylated HPLC-MS peaks. Peak 3 was not fully resolved in the reference sample, likely due
to its higher concentration. Peak 9 was not present in the reference sample. Peaks 3 and 9
each accounted for 1.5% of the total peak area. All other peak retention times matched their
corresponding reference peaks within 0.1 min, except peak 10, which matched within 0.2
min. Greater than 97% of the total peak area was accounted for by matching to the reference
sample; all peaks other than the native octreotide peak were assumed to be acylated.
4.2.4 Analysis of divalent cations by ICP-OES
The concentration of divalent cations were analyzed by ICP-OES (Perkin-Elmer Optima
2000 DV with Winlab software). Solutions containing divalent cations were diluted with
water prior to analysis. Ca2+ was detected at 396.85 nm in the radial plasma mode; Mn2+
was detected at 257.61 nm in the axial plasma mode. Each measurement was an average of
three scans.
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4.2.5 Preparation and Characterization of PLGA Nanoparticles in the
Presence of Divalent Cations
PLGA nanoparticles were prepared using a one-step, oil-in-water solvent evaporation
method. Briefly, a dichloromethane solution (2 mL) containing PLGA (50 mg) was poured
into a 50 mL glass beaker containing a 0.2% (w/v) water solution of PLA (40 mL), used
as an emulsifier, and the mixture was sonicated for 1 min using a probe sonicator (Sonics
VibraCell) at 50% power. The solvent was then evaporated for 3 hr under magnetic stirring
to harden the particles. The resulting PLGA nanoparticles were then transferred to a 50 mL
centrifuge tube and centrifuged at 919.7g for 20 min. The supernatant was discarded and
the nanoparticles were resuspended in deionized water and centrifuged 3 times to remove
excess PLA. After the final rinse, 20 mM HEPES buffer, pH 7.4 was added to a nanoparticle
concentration of ∼5 mg/mL.
The size and zeta-potential (ζ ) of PLGA nanoparticles were measured at 37◦C using a
Zetasizer Nano ZS (Malvern Instruments, UK). Each measurement was the average of 15
runs. To test the effect of divalent cations on the zeta potential of nanoparticles, concen-
trated aliquots of octreotide, CaCl2 and MnCl2 were added to the nanoparticles prior to the
measurements. In order to prevent flocculation upon the addition of divalent cations, 0.1%
(w/v) PVA was added to the HEPES buffer solution.
4.2.6 Electron paramagnetic resonance (EPR) spectroscopy of Mn in
the presence of octreotide acetate and PLGA
EPR measurements were performed on the supernatant of a solution of 15 mM MnCl2 and
2 mM octreotide in 0.1M HEPES (pH 7.4) that had been incubated in the presence and
absence of PLGA as described in section 2.4. An unincubated control solution without
PLGA was also analyzed. Prior to the EPR measurements, samples were diluted 3-fold with
a solution containing 0.1 M HEPES and 0.1M NaCl, to avoid EPR saturation, and placed in
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0.75 mm i.d. quartz capillary tubes. EPR measurements were obtained at 77K in the X-band
region with a Bruker EMX (Billerica, MA) at a microwave frequency of 9.165 GHz and
power of 1.013 mW. The 100 kHz field modulation width was 1.0 gauss. Each measurement
was the average of 3 scans.
4.2.7 Recovery of octreotide and divalent cation from PLGA via two-
phase extraction
Millicylinders or PLGA particles, which were loaded or sorbed with octreotide and/or salt
(see below), were dissolved in 1 mL methylene chloride and the octreotide and salt were
extracted with 2 mL acetate buffer (0.1 M, pH 4.0) three times. Octreotide concentration
was determined by HPLC. The encapsulation efficiency of octreotide or divalent cation was
determined by dividing the actual loading of octreotide, determined by HPLC, or divalent
cation, determined by ICP-OES, by their theoretical loading.
4.2.8 Octreotide sorption studies
Solutions of octreotide (0.2–3.0 mM, 1 mL) in HEPES buffer (0.1 M, pH 7.4) were added
to PLGA particles (10 mg, as received) and incubated (37◦C) on a rotary shaker (320 rpm)
(IKA KS 130 basic). For sorption inhibition studies, chloride salts of divalent cations (1-50
mM) or NaCl (50 mM) were added to octreotide solutions prior to incubation. HEPES buffer
was necessary to solubilize the divalent cations, which can precipitate with conventionally
used phosphate buffer ions. The amount of octreotide sorbed was determined by the loss
of octreotide from solution. Samples were removed from the incubator, centrifuged (2 min
at 9.0 rcf) (Eppendorf 5415 D), and the supernatant was analyzed by HPLC. To validate
this method of sorption quantification, an octreotide mass balance was performed at 1 and
24 hr during the sorption experiment by recovering the sorbed octreotide from the polymer
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Table 4.2 Octreotide recovery via two-phase extraction with time after incubation in pH 7.4 buffers




Aab Bb Cc Dd Ee
1 1.01 0.99 0.98 1.06 0.99
3 0.98 0.98 0.94 0.96 0.98
6 0.99 0.97 0.95 0.95 0.97
12 0.98 0.96 0.93 0.90 0.95
18 0.99 0.91 0.92 0.85 0.92
24 0.99 0.92 0.85 0.86 0.90
a 25◦C
b 100 mM HEPES
c 10 mM HEPES
d 10 mM phosphate
e 100 mM phosphate
via two-phase extraction (Table 4.2). The total amount of octreotide recoverable at 1 and
24 hr was 99±1% and 92±1%, respectively. Therefore, during sorption studies, virtually
all sorbed octreotide was non-covalently bound to PLGA, with the likelihood that a small
fraction had become covalently bound to the polymer or otherwise decomposed.
4.2.9 Preparation of PLGA millicylinders
Sieved octreotide acetate powder, or octreotide acetate and salt powder (sodium chloride,
calcium chloride or manganese chloride, <90µm), both at 5% theoretical loading (see
Table 4.3), were suspended in 62.5% (w/w) PLGA/acetone or PLGA/methylene chloride
solution. In some instances, PLGA was purified as described below prior to preparation of
millicylinders (Sections 4.2.10 and 4.2.11). The suspension was then loaded into a 3 ml
syringe and extruded into a silicone rubber tubing (0.8 mm) by a syringe pump (Harvard
Apparatus, Holliston, MA) at approximately 0.01 mL/min. The silicone tubing loaded with
suspension was dried at room temperature for 24 h followed by further drying in a vacuum
oven at 40◦C for another 48 h.
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No Salt — — — 5.07 3.1±0.2 61±3
NaCl 5.2 3.1±0.1 59.7±0.1 5.2 3.6±0.2 69±4
CaCl2 5.1 3.4±1.0 67.5±1.9 5.08 4.1±0.2 81±4
MnCl2 5.1 3.8±0.1 74.7±0.9 4.94 4.0±0.1 81±2
4.2.10 Purification of PLGA by precipitation method
100 mg of PLGA 50:50 (Absorbable Polymers International, i.v.= 0.6 dl/g) solution dis-
solved in methylene chloride (2 mL) was poured gently into excess anhydrous ether with
stirring. The precipitated PLGA was dissolved in methylene chloride and precipitated into
ether again; this process was repeated 5–6 times. Finally, the purified PLGA was dried under
vacuum.
4.2.11 Purification of PLGA by two-phase extraction method
100 mg of PLGA 50:50 (Absorbable Polymers International, i.v.= 0.6 dl/g) was dissolved in
methylene chloride (4 mL). Deionized water was added (8 mL) at 20◦C, and the mixture
was vortexed (20 s). Water phase was removed and fresh deionized water was added, the
process was repeated 5–6 times, finally the PLGA methylene chloride solution was poured
into excess anhydrous ether. The precipitated PLGA was then dried under vacuum.
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4.2.12 Octreotide release from PLGA millicylinders
PLGA millicylinders (3-4 mg) loaded with octreotide acetate and no salt, NaCl, CaCl2, or
MnCl2 (Table 4.3) were incubated in 1 mL PBS + 0.02% Tween 80, pH 7.4 (PBST) at 37◦C
for various preset times. To determine the rate of acylation and release of encapsulated
octreotide, the acylated fraction of peptide was measured in both the extract and in the
release media. For assessment in the release media, at each time point, the release media
was removed and replaced with fresh buffer, and the native and acylated octreotide content
was measured by HPLC. For assessment by extraction, release media was similarly replaced,
and peptide extraction was determined similarly as for peptide loading in Section 4.2.7.
4.3 Results and Discussion
4.3.1 Effect of divalent cations on nanoparticle zeta-potential
PLGA nanoparticles were prepared to conveniently verify that divalent cations interact with
the electric double layer of PLGA particles. The zeta-potential of the prepared particles was
-75 mV, indicating a highly negative surface potential. The presence of some surfactant was
necessary during the assessment of the effect of divalent cations on ζ to prevent flocculation
of particles, reducing the cation-free value of the zeta-potential to -11 mV as a result of
the interaction of the surfactant at the particle surface. Nevertheless, the addition of low
concentrations of MnCl2, CaCl2, and octreotide clearly shift ζ to less negative values (Table
4.4) in a concentration dependent manner, indicating that the cations do interact with the
electric double layer of PLGA nanoparticles.
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Table 4.4 Zeta-potential of PLGA 50:50 nanoparticles (diameter = 250 nm) in the absence and
presence of divalent cations at 37◦C in 20 mM HEPES buffer with 0.1% poly(vinyl alcohol), pH 7.4.
Solution Additives ζ (mV)
nonea -74.5
none -11.4
5 mM MnCl2 -0.537
5 mM CaCl2 -0.832
0.35 mM Octreotide -4.87
0.88 mM Octreotide -0.543
0.35 mM Octreotide + 5 mM MnCl2 -0.231
a no PVA, diameter = 212 nm
4.3.2 Kinetics of octreotide sorption to PLGA
Before further evaluating cation inhibition of octreotide acylation, the baseline kinetics
of octreotide sorption was determined for an initial octreotide concentration of 0.8 mM
(see Chapter 5 for more detailed kinetic studies). As shown in Figure 4.2, the sorption of
octreotide to PLGA was rapid up to 6 h. Subsequently, the increase in sorption with time
was attenuated occurring at a very low and roughly constant rate. Although sorption never
entirely reached equilibrium, possibly due to the generation of carboxylates by polymer
hydrolysis, the rapid initial sorption was complete by 24 h. For reference, the sorption
kinetics of one of the potential inhibitory divalent cations, Ca2+, was found to follow a
similar trend as that with octreotide (Figure 4.2), indicating the usefulness of the 24-hour
time point to characterize the binding behavior of the potential peptide acylation inhibitors.
Therefore, this time point was designated as time to pseudo-equilibrium.
4.3.3 Effect of divalent cations on octreotide sorption
To determine the effect of the physical properties of divalent cations on their ability to
inhibit octreotide sorption, 24-hour sorption isotherms were obtained using various concen-
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trations of different cations in HEPES buffer (0.1 M, pH 7.4). Octreotide sorption isotherms
containing 0, 1, 15, and 50 mM MgCl2 or CaCl2 are shown in Figure 4.3. Langmuir-like
behavior was observed in the absence of salt and only for 1 mM divalent salt concentration;
for higher concentrations of divalent salt, the amount of sorbed peptide appeared to increase
sigmoidally with equilibrium octreotide concentration. Ca2+ was more effective at inhibiting
sorption than Mg2+ at all concentrations tested.
Next, the effect of chloride salts of other divalent (Sr2+, Ni2+, Mn2+) and monovalent
(Na+) cations were investigated to determine if such cations could inhibit sorption more
effectively than Ca2+ (Figure 4.4). The octreotide adsorption was very strongly inhibited in
the presence of Mn2+, and in the presence of 15 mM divalent cations, inhibition decreased
in the order: Mn2+ > Ni2+ > Sr2+, Ca2+ > Mg2+. When 50 mM NaCl was added to the
HEPES buffer, the amount of octreotide sorbed decreased slightly compared to the salt-free
octreotide isotherm (see Figure 4.3), but was greater than in the presence of 15 mM divalent
chlorides. For example, the amount of sorption from an initial concentration of 2 mM
octreotide was reduced from 70 µmol/gPLGA for 50 mM Na+ to 66, 32, and 2 for 15 mM
Mg2+, Ca2+, and Mn2+, respectively.
The reduction in the amount of octreotide sorbed upon the addition of salt suggests that
ionic strength may play a role in the interaction of octreotide with PLGA at pH 7.4. The
ionic strength of octreotide solutions in HEPES buffer without salts is 50 mM, while the
addition of 15 mM divalent cation chloride salt or 50 mM NaCl increased the ionic strength
to approximately 100 mM. However, the increased ionic strength cannot account for the
decreased sorption of octreotide to PLGA in the presence of divalent cations relative to Na+.
The overall binding strength of an ion with its ligand results from the balance of the
intrinsic binding affinity of complexation (exothermic) and differences in hydration resulting
from the liberation of water upon binding (endothermic) [129, 130]. The intrinsic binding
affinity of divalent cations may change in solution for cations susceptible to oxidation, such
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as Mn2+, which may react to form ions with increased positive charge [131]. Furthermore,
hydrolysis of hydrated aquo-cations, X[H2O]n 2+, where X is a cation in solution, may
result in the reduction of their positive charge, (e.g. X[H20]n−1[OH]+) [132]. The order of
effectiveness for the group II cations suggests that with increasing size, the higher hydration
energy of Ca2+ may compensate for the loss of intrinsic binding affinity present at lower
charge densities (e.g., as for Mg2+). Thus, the relatively poor inhibition of Mg2+ may be
due to a higher ratio of bound cation to PLGA carboxylates at quasi-equilibrium for Ca2+
than for Mg2+.
For transition metal cations, complexation with a ligand causes field splitting of the
d orbitals, resulting in crystal field stabilization. In the high-spin (weak field) electron
configuration, Mn2+ is not stabilized by crystal field splitting, whereas Ni2+ is stabilized
[131]. Thus, one would expect Ni2+ to be a more effective inhibitor of octreotide adsorption
if the crystal field stabilization energy were the most significant component affecting cation
binding. One possibility for the increased effectiveness of Mn2+ is the difference in rate
constant for the exchange of water, which is three orders of magnitude higher for Mn(H20)2+
than Ni(H20)2+ [132]. There also exists a potential for Mn2+ oxidation to Mn3+ or other
oxidized manganese species. In support of this notion, the Pourbaix diagram for manganese
shows that the stability of Mn2+ decreases with increasing pH and is unstable above pH 7.6
[131].
To test the stability of Mn2+ in the chloride salt solution containing octreotide acetate in
the presence and absence of PLGA, the hyperfine splitting of Mn2+ was evaluated using
EPR spectroscopy. The typical hyperfine splitting of Mn2+ was observed for all spectra. No
significant difference in the peak shape or intensity of the EPR spectra was observed for
the incubated samples in the absence or presence of PLGA, relative to the non-incubated
control (Figure 4.5). Therefore, the inherent inhibitory potential of Mn2+ in the presence of
octreotide in the 24-h sorption isotherms was unlikely caused by other oxidized Mn-species,
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such as Mn3+, which is EPR silent [133].
4.3.4 Long-term interaction of octreotide with PLGA
Long-term sorption studies were performed to determine the effect of 15 mM CaCl2 and
MnCl2 on the sorption and acylation of octreotide (Figure 4.6). In the absence of salt, the
onset of octreotide sorption occurred rapidly (1 day), followed by a continuous increase
in the total amount of octreotide in solution after 3 days. Octreotide acylation products
appeared at 3 days and continuously increased to 32% of total octreotide in solution by 21
days. In the presence of modest concentrations of CaCl2 or MnCl2, the peak amount of
sorption occurred later (14 days). Exhibiting a similar delay, octreotide acylation products
did not appear until 7 days and increased to 14% of total octreotide in solution by 21 days
in the presence of CaCl2. While the onset of acylation was not delayed in the presence of
MnCl2, the amount of acylation at 21 days was 13%, similar to that found with CaCl2 and
less than half that of the salt-free value. The similar effectiveness of Ca2+ and Mn2+ is
consistent with our suggestion that several mechanisms may contribute to the inhibition
of sorption by divalent cations. The oxidation of Mn2+ to form MnO(s) may contribute to
the reduced effectiveness of MnCl2 in long-term studies. Solutions of MnCl2 in HEPES
buffer displayed visible signs of a solid brown precipitate, typical of MnO, after 2–3 weeks
at room temperature. Another possibility is that differences between the microclimate
environment within the pores and the HEPES buffer solution altered the water-exchange
rates or the pKa of hydrolysis of the aquo-cations. Nevertheless, these results strongly
support the previously formed hypothesis that some type of sorption to PLGA is involved in
the acylation mechanism [90], and that inhibiting adsorption is a useful strategy to minimize
octreotide acylation.
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Table 4.5 Effect of PLGA composition and excipients on octreotide acylation during millicylinder
production. Theoretical octreotide and excipient loading were both 5 wt%.









a PLGA purified as described in Section 4.2.10.
b PLGA purified as described in Section 4.2.11.
4.3.5 Effect of salts on peptide acylation when encapsulated in PLGA
The microclimate pH within PLGA controlled-release depots has been reported to be acidic
[86], protonating the carboxylate groups responsible for the peptide interaction and making
them unavailable for sorption. However, the polymer carboxylates can form a salt with
the peptide during drying. During release, the microclimate pH is often acidic but variable
[134]. Furthermore, the monomer and oligomers or lactic and glycolic acid have pKa’s that
are very low (e.g., 3.1–3.6), so a significant fraction of carboxylates will be ionized within
the common microclimate pH range (e.g., 2.5–5) [135].
To determine if the divalent cations could inhibit acylation of encapsulated peptide,
PLGA millicylinders containing octreotide acetate and either no salt, NaCl, CaCl2, or
MnCl2 (Table 4.3) were prepared by a solvent extrusion method [44], except that methy-
lene chloride was used in place of acetone as a carrier solvent. In control studies, where
extrusion was performed with an end-capped polymer (PLGA 50:50, i.v.=0.6 dl/g) and
acetone, we observed strong acylation of 5% loaded octreotide (65±3% acylation) following
solvent extrusion. This acylation was strongly inhibited by 5% loaded divalent salts (e.g.,
CaCl2: 14±1% and MnCl2: 23±1% acylation) relative to 5% loaded NaCl control (57±3%
acylation) (Table 4.5).
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The cause of this acylation is unknown, but low molecular-weight impurities may play
a role. To test this hypothesis, PLGA was purified either by precipitation into ether or
two-phase extraction prior to octreotide encapsulation. The amount of native octreotide
recovered from the millicylinders made using purified PLGA was double the amount recov-
ered from unpurified PLGA (Table 4.5), strongly suggesting that water-soluble oligomers
are involved in octreotide acylation within PLGA millicylinders. Both purification methods
appeared to remove PLGA impurities with equal efficiency, but did not significantly increase
the amount of native octreotide recovered from millicylinders loaded with CaCl2 or MnCl2.
Following encapsulation with methylene chloride, no peptide acylation was observed
although encapsulation efficiency of both peptide and encapsulated salts was slightly lower,
i.e., ∼60–80% (Table 4.3), than traditionally with acetone [44]. The resulting millicylinders
with initially native octreotide were then incubated in PBST at 37◦C for 28 days. As encap-
sulated salts may modulate porosity, osmotic pressure, water uptake, transport of soluble
oligomers, and pH, and therefore peptide acylation rate in the PLGA-peptide system [118],
the addition of NaCl was used as an additional control. For the peptide release study, we
recorded the fraction of extractable peptide remaining in the polymer, as octreotide is known
to be unstable at physiological pH [136]. To assess acylation kinetics, we resolved the
acylated peptide fraction from the acylated fraction appearing in the polymer extract (Table
4.6), as well as the total peptide in the release media (assuming similar decomposition rates
between acylated and native peptide species, Table 4.7). The total extractable octreotide
remaining within the millicylinders decreased steadily to approximately 25% over the course
of 4 weeks for all formulations. Relative to the no-salt and NaCl controls, the addition of the
divalent chlorides of Ca2+ or Mn2+ reduced the fraction of acylated octreotide extractable
from the millicylinders at 7 days by approximately 75% from 8% to under 2%. The amount
of acylation within the millicylinders formulated with divalent chlorides remained lower
than the no-salt and NaCl control at all time-points, although the benefit from the addition of
divalent chlorides decreased with time, likely due to the release of the salts during incubation.
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Future studies will focus on maximizing salt content, distribution, and retention to maintain
the highest competitive advantage for the anionic binding sites on the polymer.
4.4 Conclusions
A new class of inhibitors of the sorption and acylation of a model peptide, octreotide ac-
etate, has been described. At neutral pH, all cations studied inhibited octreotide sorption
to PLGAthe inhibiting effect of the cations increased in the order: Na+ < Mg2+ < Ca2+,
Sr2+ < Ni2+ < Mn2+. Long-term sorption studies in the presence of CaCl2 and MnCl2 indi-
cated that disrupting peptide sorption to PLGA with the inorganic divalent cation inhibitors
translates to inhibition of peptide acylation. Acylation of octreotide encapsulated in PLGA
millicylinders containing equivalent weight ratio CaCl2 or MnCl2 relative to peptide was
also inhibited relative to no salt or NaCl controls during encapsulation or release incubation.
In a future report we will demonstrate the strong inhibition of octreotide acylation afforded
by divalent cations both during release of octreotide from PLGA microspheres.
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Table 4.6 Long-term stability of octreotide extracted from PLGA millicylinders.
Formulation Time (day) Native (%) Acylated (%) Total (%)
No Salt
7 88.7±6 7.8±1 96.5±6
14 76.6±1 10.2±1 86.8±2
21 36.3±4 5.8±2 42.1±5
28 18.5±4 2.5±1 21.0±5
NaCl
7 88.2±5 7.0±1 95.1±5
14 53.5±11 7.9±2 61.4±13
21 31.5±5 5.2±1 36.7±6
28 20.8±2 5.3±1 26.1±3
CaCl2
7 76.4±6 1.5±1 77.9±6
14 61.3±3 3.0±1 64.3±3
21 31.3±2 2.1±1 33.3±2
28 18.9±2 3.5±1 22.4±3
MnCl2
7 82.6±3 1.7±1 84.3±3
14 55.4±2 2.8±1 58.2±3
21 31.5±2 3.2±1 34.7±2
28 16.3±4 3.8±1 20.1±4
Table 4.7 Long-term release of native and acylated octreotide from PLGA millicylinders.
Formulation Time (day) Native (%) Acylated (%) Total (%)
No Salt
7 0.8±0 0 0.8±0
14 4.6±0 0.8±0 5.6±0
21 32.0±3 7.6±1 39.6±4
28 42.7±6 14.7±3 57.4±9
NaCl
7 1.7±1 0 1.7±1
14 16.8±8 3.1±1 19.9±7
21 37.0±12 12.6±3 49.6±14
28 43.8±9 19.2±2 63.0±10
CaCl2
7 8.8±1 0 8.8±1
14 17.7±1 0.9±0 18.6±1
21 38.8±1 4.2±0 43.0±1
28 43.7±2 7.2±1 50.9±3
MnCl2
7 11.7±2 0 11.7±2
14 23.8±2 1.7±0 25.5±2
21 32.2±2 4.8±2 37.0± 0
28 39.6±2 11.2±2 50.8±1
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4.5 Appendix
Initial investigations for inhibitors of peptide sorption included water-soluble divalent cation
salts, organic acids, and other excipients. This Appendix briefly reviews these preliminary
studies and presents data for polycations as an additional class of sorption inhibitors..
4.5.1 Preliminary investigation into the effect of excipients on oc-
treotide sorption to PLGA
The effect of various excipients and pretreatments on octreotide adsorption to PLGA was
quantified by comparing the amount adsorbed at a given equilibrium concentration to the
amount adsorbed at that concentration predicted by the Langmuir model for sorption from
0.1M phosphate buffer, pH 7.4 (data not shown). Acids with pKas below PLGA oligomers,
such as maleic (pKa=1.9), oxalic (1.3), or trifluoroacetic acid (-0.2), were chosen to study
whether they could displace octreotide by disrupting ionic interactions between octreotide
and PLGA oligomers. The addition these acids at various molar excesses resulted in an
inhibition of the amount adsorbed by 1–21% compared to value predicted by the Langmuir
model (Table 4.8). These values of inhibition are not significant relative to the error of the
Table 4.8 Effect of sodium salts of weak acids, trifluoroacetic acid, and Polysorbate 80 on oc-














Maleic acid 3x 103.8 (2.7) 81.1 90.8 11
Oxalic acid 3x 102.3 (5.0) 79.3 89.6 11
TFA 1x 119.3 (1.5) 90.0 103.3 13
TFA 3x 117.2 (2.0) 81.8 101.6 19
TFA 10x 128.7 (1.3) 77.1 97.1 21
TFA 30x 105.5 (2.0) 91.6 92.2 1
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Langmuir model (i.e., the error in predicting the same standards used to fit the isotherm).
4.5.2 Polycations as inhibitors of octreotide sorption to PLGA
Polycations are another class of octreotide sorption inhibitors to PLGA. As shown in Fig-
ure 4.7, octreotide sorption was reduced in the presence of 0.24 mg/mL poly(arginine) or
>0.2 mg/mL poly(ethyleneimine) (PEI). At PEI concentrations greater than 1.0 mg/mL,
octreotide sorption to PLGA is minimal. This concentration of PEI contains ∼24 mM
positively charged monomeric units, comparing well to the concentration of divalent cations
necessary for similar sorption inhibition. Unfortunately, most polycations are not generally
regarded as safe for use in humans [137, 138, 139, 140].
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Figure 4.1 (A) Sample chromatogram of reference sample of acylated octreotide products. (b)
Sample chromatogram of acylated octreotide products in solution after 21 days incubation in the
presence of PLGA 50:50 at 37◦C.
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Figure 4.2 Kinetics of octreotide acetate sorption to PLGA 50:50 in the presence of 15 mM CaCl2
(), MnCl2 (N), no salt (•), and kinetics of Ca2+ (◦) sorption to PLGA during 24 h incubation in
peptide-free 0.1M HEPES buffer solution, pH 7.4 at 37◦C. PLGA was 10 mg in 1 mL of buffer
solution. Initial octreotide and calcium chloride concentrations were 0.8 and 15 mM, respectively.
Dotted trendlines shown for clarity.
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Figure 4.3 Effect of (A) MgCl2 and (B) CaCl2 on octreotide acetate sorption to PLGA 50:50 at 0
(◦), 1 (•), 15 (N), and 50 () mM salt concentrations after 24 hr incubation in 0.1M HEPES buffer
solution, pH 7.4 at 37◦C. PLGA was 10 mg in 1 mL of buffer solution.
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Figure 4.4 Effect of 15 mM Mg2+ (), Ca2+ (4), Sr2+ (N), Ni2+ (◦), and Mn2+ (•) chloride and
50 mM NaCl () on octreotide sorption to PLGA 50:50 after 24 hr incubation in 0.1M HEPES buffer
solution, pH 7.4 at 37◦C. PLGA was 10 mg in 1 mL of buffer solution.
Figure 4.5 EPR spectra of (A) unincubated MnCl2, (B) MnCl2 and octreotide incubated without
PLGA, and (C) MnCl2 and octreotide incubated with PLGA.
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Figure 4.6 Octreotide sorption and formation of acylated products, native (•), acylated (◦), and
total (H) octreotide, during incubation of PLGA at 37◦C in 0.1M HEPES buffer solution, pH 7.4
containing (A) no additional salt, (B) 15 mM CaCl2, and (C) 15 mM MnCl2. Initial octreotide
concentration was 0.2 mM and PLGA was 10 mg in 1 mL of buffer solution.
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Figure 4.7 Effect of 0.24 mg/mL poly(arginine) (N) 0.2 (◦), 1.0 (•), and 2.0 () mg/mL
poly(ethyleneimine) on octreotide acetate sorption to PLGA 50:50 after 24 hr incubation in 0.1M
HEPES buffer solution, pH 7.4 at 37◦C. PLGA was 10 mg in 1 mL of buffer solution.
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Chapter 5
Kinetics of Peptide Sorption to PLGA
5.1 Introduction
Due to the important role of peptide sorption to PLGA as the initial step on the acylation
pathway, a detailed understanding of peptide sorption behavior is critical for the develop-
ment of a rational formulation approach to minimize peptide acylation. The kinetics of
peptide sorption is important to understand the mechanism of sorption and acylation with
PLGA. Understanding peptide-polymer interactions is also useful because they can affect
encapsulation into delivery systems and influence release behavior [89].
In this Chapter, we study the effect of initial concentration and ionic strength on the
kinetics of peptide sorption to PLGA, compare the sorption kinetics of two model peptides,
octreotide and leuprolide, which have different structures and conformational flexibility, and
present a biexponential kinetic model that describes the sorption process well.
Understanding the mechanism and rate-limiting step of peptide sorption to PLGA is
important to help identify potential strategies to inhibit sorption and acylation in PLGA. The
sorption process is typically subdivided into the following steps:
1. diffusion of sorbate to the surface
2. interaction of sorbate with sorbing substance
3. structural rearrangements, if applicable
4. desorption from sorbing substance, if applicable
5. intraparticle diffusion, if applicable
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The rate-limiting step of peptide sorption may be affected by solution properties, peptide
concentration, the extent of surface coverage, or surface charge density, possibly resulting in
a transition towards mass-transfer limited behavior.
Biexponential sorption kinetics have previously been observed for peptide sorption
[141, 142], substrate binding [143], hydrogen-deuterium exchange in proteins [144, 145],
and many other processes [146, 147, 148, 149]. The sorption of octreotide to PLGA was
also found to follow biexponential kinetic behavior (see Figure 4.2):
Psorb(t) = N f ast(1− e−k f t)+Nslow(1− e−ks t) (5.1)
where Psorb(t) is the amount of peptide sorbed, N f ast and Nslow are the population of
peptide molecules sorbing under ’fast’ and ’slow’ kinetics (N f ast +Nslow = 185 µmol/g
PLGA, the total number of PLGA acid end-groups for RG502H), and k f and ks are the
apparent pseudo-first-order rate constants.
There is no common agreement in the literature concerning the meaning of the of the
two rate constants for macromolecular binding/sorption interactions [150]. Three expla-
nations for biexponential sorption kinetics have been discussed in the literature: surface
site heterogeneity [150], conformational rearrangements [141, 142, 144, 151], and mass
transport limitations [152, 153].
Surface heterogeneity may result from peptide binding to regions of the PLGA surface
with different surface charge density or polymer functional groups at the interface (e.g.
methyl side chains from lactic acid units). Furthermore, peptide binding to the PLGA
surface may occur at different peptide orientations, or an equilibrium may exist between
multiple peptide conformations, each with individual binding affinities. Evans et al. [154]
noted that due to diverse interfacial features potentially available on a sorbing substance,
binding peptides may reconform to recognize different surface features.
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Conformational rearrangements upon adsorbing to surfaces, which are often observed
for proteins [155, 156, 157, 158], have also been observed for peptides [141, 142, 159].
Furthermore, PLGA itself has been shown to rearrange upon changes in the hyrophobicity
of the interface [160].
A detailed physical interpretation of the derived kinetic parameters is complicated and
beyond the scope of this present work. The use of the biexponential model is not intended to
imply that there are necessarily only two types of interactions (e.g. heterogeneous binding
sites, multiple binding conformations, post-binding conformational reorientations, or a
change in the rate-limiting step), but that the inclusion of a second exponential term acts to
partially deconvolute the complex sorption behavior [161].
5.2 Materials and Methods
5.2.1 Materials
Octreotide acetate was obtained from Novartis (Basel, Switzerland). Leuprolide acetate (Lot
No. 071002) was purchased from Shanghai Shinjn Modern Pharmaceutical Technology Co.
(Shanghai, China). PLGA 50:50 (Resomer R© RG502H) was purchased from Boehringer-
Ingelheim GmbH (Ingelheim, Germany). (Hydroxyethyl)-piperazine-(ethanesulfonic acid)
(HEPES) was purchased from Sigma-Aldrich Chemical Co. (St. Louis, MO). All other
reagents used were of analytical grade or purer and purchased from commercial suppliers.
5.2.2 Investigation of octreotide sorption kinetics
Solutions of octreotide (0.26–1.8 mM, 1 mL) or leuprolide (0.42 mM) in HEPES buffer (0.1
M, pH 7.4) were added to PLGA particles (10 mg, as received) and incubated (37◦C) on a
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rotary shaker (320 rpm) (IKA KS 130 basic). Samples were removed from the incubator at
selected time-points, centrifuged (2 min at 9.0 rcf) (Eppendorf 5415 D), and the supernatant
was analyzed by HPLC. The amount of octreotide sorbed was determined by the loss of
octreotide from solution. Quantification of peptide sorption by the difference method was
previously validated by mass balance after recovery of sorbed octreotide via two-phase
extraction (Section 4.2.8).
5.2.3 Analysis of octreotide by HPLC
The concentration of octreotide was determined by RP-HPLC, similarly as described by
Murty, et al. [112]. Injection volumes of 20 µL were loaded onto a Nova Pak C-18 column
(3.9 x 150 mm, Waters) for RP-HPLC (Waters Alliance R©) analysis using UV detection (280
nm). Solvent A was 0.1% TFA in acetonitrile and Solvent B was 0.1% TFA in water. A
linear gradient of 25 to 35% A in 10 min, with a flowrate of 1.0 mL/min was used.
5.2.4 Model of peptide sorption to PLGA and estimation of kinetic
parameters
The parameters of the biexponential kinetic model (Equation 5.1) for peptide sorption to
PLGA were obtained by non-linear regression to minimize the sum of the squared error
between the amount of peptide sorbed determined experimentally and predicted by the
model. The values of k f and ks were assumed to be independent of concentration and
ionic strength. Although it is reasonable to presume that k f and ks could have a non-trivial
dependence on ionic strength, it was assumed that the change in k f and ks with ionic strength
was small relative to other contributions to the observed kinetics.
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Table 5.1 Parameters of biexponential kinetic model for data shown in 5.1(a), at various initial










0.26 8 177 4
0.39 13 172 7
0.54 22 163 12
0.87 42 143 23
1.80 93 92 50
5.3 Results and Discussion
5.3.1 Effect of Octreotide Concentration on Octreotide Sorption Ki-
netics
The kinetics of octreotide sorption to PLGA as a function of concentration is shown in
Figure 5.1. As the initial concentration of octreotide increases, the initial rate of sorption
increases, while the slope of the constant phase decreases (see Fig. 5.1(b)), suggesting a
shift in the kinetic mechanism or rate-limiting step at higher concentrations.
Octreotide sorption to PLGA was well described by a biexponential model (Equation
5.1). Table 5.1 summarizes the fitted parameters for various initial concentrations of oc-
treotide in the linear region of the octreotide sorption isotherm. A relationship between
concentration and the model parameters is obvious, although we have not collected sufficient
kinetic data (e.g. at high concentrations) to discern this relationship. The potential shift in
the mechanism or rate-limiting step of octreotide sorption at various initial concentrations is
shown quantitatively as the ’fast’ component of the observed kinetics shifting towards the
predominant pathway at higher initial concentrations of octreotide.
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Table 5.2 Parameters of biexponential kinetic model fit for data shown in Figure 5.2, with ionic
strength modulated by buffer concentration and type. Initial octreotide concentration was 0.4 mM.













HEPES, 10 5 31 154 17
Phosphate, 10 24 29 156 16
HEPES, 100 50 10 175 5
Phosphate, 100 237 7 178 4
5.3.2 Effect of Ionic Strength on Octreotide Sorption Kinetics
Having found that the amount of octreotide sorbed from solutions of constant ionic strength
is independent of the concentration of HEPES buffer, and low concentrations of phosphate
(see Section 3.2), the ionic strength of octreotide solutions was adjusted by varying the buffer
type and concentrations. This allowed for the investigation of ionic strength without the
addition of varying amounts of sodium cations to adjust ionic strength, which could act as
weak inhibitors of octreotide sorption to PLGA (see Figure 4.4), although a later study found
that the amount of octreotide sorbed from solutions of constant ionic strength is independent
of the concentration of sodium, HEPES buffer, and low concentrations of phosphate (Figure
5.3)— at high phosphate concentrations, octreotide is unstable (see Section 3.2).
As the ionic strength was reduced from 237 GA24 mM, the amount of octreotide sorbed
increased substantially (Figure 5.2, model parameters in Table 5.2), in support of the concept
of electrostatic interaction between octreotide and the PLGA carboxylates play a crucial
role in the initial sorption mechanism. No significant difference in the amount of octreotide
sorbed was observed at an ionic strength <24 mM, possibly resulting from the convergence
of the activity coefficient towards the value of 1.
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Table 5.3 Parameters of biexponential kinetic model fit for peptides sorbed to PLGA from solutions
of 0.4 mM (A) octreotide in 0.1 M HEPES, pH 7.4 at 25◦C (data shown in Fig. 5.5), (B) leuprolide
in 0.1 M HEPES, pH 7.4 at 37◦C (data shown in Fig. 5.4), and (C) octreotide in 0.1 M HEPES, pH
7.4 at 37◦C (fit singularly for comparison).
Series N f ast(µmol/gPLGA)
Nslow
(µmol/gPLGA) N f ast (%) k f (hr
−1) ks (hr−1)
A 3 182 1 0.74 8.70×10−4
B 21 164 12 2.65 1.48×10−3
C 14 171 8 1.15 2.95×10−3
5.3.3 Comparison of Leuprolide and Octreotide Sorption Kinetics
Peptide structural effects on acylation are not currently well understood [94], but may be
due in part to their effect on sorption to PLGA. We compared the sorption kinetics of two
model peptides, octreotide and leuprolide, which have different structures, net charge, and
conformational flexibility. As shown in Figure 5.4 (also see Table 5.3), the initial rate of
leuprolide sorption was substantially faster than for octreotide, increasing with a reduced
slope at longer times, behaving in a less biexponential manner than octreotide. This sug-
gests that one or more of the limiting steps in the octreotide sorption mechanism that are
deconvoluted by the biexponential model occur at a faster rate for leuprolide.
Kang and Schwendeman [162] measured the diffusion coefficient of bodipy dye in an
end-capped low molecular-weight PLGA 50:50. They found the diffusion coefficient to
be ∼1×10−11 cm2/s at 37◦C. The water uptake of free-acid RG502H should substantially
increased relative to the more hydrophobic end-capped PLGA used in the Kang and Schwen-
deman study, possibly increasing diffusivity of octreotide, relative to bodipy, by a factor
10-100, a value high enough to potentially allow for kinetic control of the sorption process.
Assuming that the sorption of either peptide is not mass-transfer limited in the well-
mixed conditions of the sorption experiment or in the polymer phase, if partitioning occurs,
differences in the observed kinetics would likely be due to structural effects.
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While we cannot ascertain how structural effects or flexibility play a role in the different
sorption kinetics of octreotide and leuprolide, Peelle et al. [163] has shown that increased
flexibility improved peptide affinity to II-VI semiconductors by mitigating the effects of
down-regulating amino acids that decreased adsorption affinity upon restructuring conforma-
tionally post-binding. Conversely, affinity may be improved in conformationally restricted
peptides that retain up-regulating amino acids at spatially proximal distances.
Furthermore, based on peptide adsorption kinetics obtained using SPR, Seker et al. [141]
provide evidence that molecular features, such as a loop constraint, can exert significant
influence on peptide adsorption onto surfaces. The fact that linear-PTSTGQA peptide
exhibited biexponential adsorption behavior, while cyclic-CPTSTGQAC adsorption was
described by a single exponential, suggests that the adsorption process for the linear form
may involve an additional event or step that does not occur in the cyclic-CPTSTGQAC
adsorption process. They suggested this additional step may involve peptide conformational
rearrangement or repositioning of the linear peptide on the surface that occurs after the initial
peptide binding event. However, the exact nature of the proposed mechanism is unclear and
inconsistent– in a subsequent review by the same authors [154], they presented the same
graph with the peptide assignments flip-flopped and stated that the cyclic peptide, rather
than the linear one, displayed the biexponential kinetics because it required an additional
folding step that was inaccessible to the linear one.
5.3.4 Temperature Dependence of Octreotide Sorption
Octreotide sorption to PLGA was significantly temperature dependent (Figure 5.5). Re-
ducing the temperature below the hydrated Tg (∼30◦C), from 37 GA 25◦C, dramatically
attenuated the rate and extent of sorption (Table 5.3), while no octreotide sorption was
observed at 4◦C. Several factors could contribute to the temperature effect on octreotide
sorption, including its effect on hydrophobic interactions [164], hydration of the polymer
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[40], polymer mobility, and diffusivity of species within the polymer phase. For example,
Kang and Schwendeman [162] found that the diffusion coefficient of bodipy dye in an
end-capped PLGA 50:50 of similar molecular weight as RG502H varied over 3 orders of
magnitude from 22 GA 45◦C, a temperature range spanning the hydrated glass-transition
temperature [40], and was too slow to measure at 4◦C.
5.4 Conclusions
The kinetic profiles of peptide sorption to PLGA were investigated at various solution
conditions. The rate and extent of sorption is reduced at low octreotide concentrations,
high solution ionic strength and low temperature, becoming completely attenuated at 4◦C,
suggesting polymer mobility plays a critical role in the sorption interaction. Leuprolide sorbs
to PLGA at a greater rate and extent than octreotide, possibly due to structural differences,
although mass-transfer limitations may also contribute. A biexponential model described
the sorption profiles extremely well, and a relationship between concentration and the model
parameters is obvious, although kinetic data at high concentrations will be required in order
to discern this relationship.
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Figure 5.1 (A) Kinetics of octreotide sorption to PLGA 50:50 from solutions of 0.26 (N), 0.39 (4),
0.54 (•), 0.87 (◦), 1.80 () mM octreotide in 0.1 M HEPES, pH 7.4 at 37◦C and fits to biexponential
model (solid lines). (B) Normalized kinetic data (same symbols). Model fits for 0.26 and 0.54 mM
omitted for clarity.
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Figure 5.2 Effect of ionic strength on octreotide sorption kinetics to PLGA 50:50 (Boehringer-
Ingelheim RG502H) at 37◦C in solutions of pH 7.4. The ionic strength was adjusted using buffer type
and concentration: 10mM HEPES buffer (I = 4 mM, N), 10 mM phosphate buffer (23 mM, ◦), 0.1M
HEPES buffer (49 mM,4), 0.1 M phosphate buffer (236 mM, •). Initial octreotide concentration
was 0.4 mM.
Figure 5.3 Effect of buffer type and concentration (pH 7.4) on octreotide sorption to 10 mg PLGA
50:50 (Boehringer-Ingelheim RG502H) from 300 mM ionic strength solutions (adjusted by NaCl) at
37◦C. Amount sorbed: shaded area; amount remaining in solution: white area.
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Figure 5.4 Comparison of leuprolide (•) and octreotide (4) sorption to PLGA 50:50 (Boehringer-
Ingelheim RG502H) at 37◦C in solutions of 0.1 M HEPES buffer, pH 7.4. Initial peptide concentration
was 0.4 mM.
Figure 5.5 Effect of temperature on octreotide sorption to PLGA 50:50 (Boehringer-Ingelheim
RG502H) in solutions of 0.1 M HEPES buffer, pH 7.4. Initial octreotide concentration was 0.4 mM.
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Chapter 6
Sorption Behavior of Peptides to PLGA
6.1 Introduction
Due to the important role of peptide sorption to PLGA as the initial step on the acyla-
tion pathway, a detailed understanding of peptide sorption behavior is important for the
development of a rational formulation approach to minimize peptide acylation. Understand-
ing peptide-polymer interactions is also useful because they can affect encapsulation into
delivery systems and influence release behavior [89].
Although there are multiple reports of peptide adsorption to surfaces [141, 142, 165, 166],
detailed studies of the sorption of peptides to PLGA have been limited. For example, Tsai
et al. [167, 168] investigated in detail the effect of physical factors and solution properties
on the adsorption kinetics and isotherms of salmon calcitonin, the 8-22 amino acid portion
of salmon calcitonin (CT15), triptorelin, and vapreotide to end-capped RG503 (see Table
3.1 for characteristics of RG503). Calcitonin is a 32-amino acid hormone that may sorb
similarly to proteins due to its larger molecular weight and secondary structure. Triptorelin is
a gonadotropin-releasing hormone agonist and vapreotide is somatostatin analogue, similar
in structure to leuprolide and octreotide, respectively—peptides used in this study. The
authors selected two peptides, CT15 and vapreotide, that did not sorb to RG503. They
also reported limited solubilities for both vapreotide and triptorelin. As a result, only data
for calcitonin and triptorelin at low concentrations was reported. The authors presumed
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the sorption was multilayer based on geometric calculations, and presented hypothetical
schemes of peptide aggregating prior to sorption or peptide aggregation induced by sorption.
The absence of CT15 sorption suggests that physical instabilities may play a role in the
adsorption of calcitonin, although it is also possible that the deleted sequences specifically
interact with PLGA. The selection of poorly soluble small peptides, which are unstable
in solution, limit the applicability of their conclusions to more soluble peptides such as
leuprolide or octreotide.
In this study, the first detailed investigation into the sorption of water-soluble low molec-
ular weight peptides to free-acid PLGA, we obtain sorption isotherms across a broad range
of peptide concentration at various pH and assess the reversibility of sorption at various
solution conditions, with the goal of gaining insight into the factors and forces influencing
the type and extent of sorption.
6.2 Materials and Methods
6.2.1 Materials
Octreotide acetate was obtained from Novartis (Basel, Switzerland). Leuprolide acetate
(Lot No. 071002) was purchased from Shanghai Shnjn Modern Pharmaceutical Technol-
ogy Co. (Shanghai, China). PLGA 50:50 (Resomer R© RG502H, RG503H, and RG504H)
was purchased from Boehringer-Ingelheim GmbH (Ingelheim, Germany). (Hydroxyethyl)-
piperazine-(ethanesulfonic acid) (HEPES), calcium chloride (CaCl2), and trifluoroacetic acid
(TFA) were purchased from Sigma-Aldrich Chemical Co. (St. Louis, MO). Diethylpiper-
azine (DEPP) was purchased from Acros Organics (Geel, Belgium). All other reagents used
were of analytical grade or purer and purchased from commercial suppliers.
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6.2.2 Analysis of octreotide by HPLC
The concentration of octreotide, was determined by RP-HPLC, similarly as described by
Murty, et al. [112]. Injection volumes of 20 µL were loaded onto a Nova Pak C-18 column
(3.9 x 150 mm, Waters) for RP-HPLC (Waters Alliance R©) analysis using UV detection (280
nm). Solvent A was 0.1% TFA in acetonitrile and Solvent B was 0.1% TFA in water. A
linear gradient of 25 to 35% A in 10 min, with a flowrate of 1.0 mL/min was used.
6.2.3 Octreotide sorption studies
For desorption studies, solutions of 1 mM octreotide (1 mL for particles, 4 mL for film) in
0.1 M HEPES buffer, pH 7.4 were added to PLGA particles (10 mg, as received) or a PLGA
film prepared according to D conditions (see Table 3.2 for more information) and incubated
(37◦C) on a rotary shaker (320 rpm) (IKA KS 130 basic). HEPES buffer was necessary
to solubilize the calcium used in the desorption study and the divalent cations used for
inhibition studies (see Section 6.2.4, and Chapter 4, respectively), which can precipitate with
conventionally used phosphate buffer ions. For 24-hr sorption isotherms, peptide solutions
with initial concentration of 0.2–4.0 mM in 0.1 M HEPES buffer, pH 7.4, 0.1 M MES
buffer, pH 5.5, or 0.05 M DEPP buffer, pH 4.0 were used. Samples were removed from
the incubator, centrifuged (2 min at 9.0 rcf) (Eppendorf 5415 D), and the supernatant was
analyzed by HPLC. The amount of peptide sorbed was determined by the loss of peptide
from solution for particles, and by two-phase extraction of sorbed peptide for films.
6.2.4 Desorption of octreotide from PLGA 50:50
Samples prepared as described above were gently centrifuged and the supernatant was
removed; the amount initially sorbed was ∼650 nmol for RG 502H particles, ∼360 nmol
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for RG503H particles, and ∼300 nmol for RG 502H films. After removal of the supernatant
and rinsing with deionized water twice, desorption solutions containing 50 vol% methanol
(MeOH) in water, 0.1 M diethylpiperazine (DEPP, pH 4.0), 2 M CaCl2 in 0.1 M HEPES
(pH 7.4), 1 mg/mL PEI in 0.1 M acetate buffer, pH 4.0, 0.1% TFA in 0.1 M HEPES, pH
7.0, 5% SDS, or only 0.1 M HEPES, pH 7.4 were separately added to the residual PLGA
and incubated for 24 hr at 37◦C. Additionally, samples containing 0.1 M HEPES, pH 7.4
desorption buffer were incubated for 24 hr at 4◦C. All samples except the 5% SDS were then
removed from the incubator, centrifuged, and the supernatant analyzed by HPLC. Because
SDS interferes with the RP-HPLC analysis, desorption was assessed by recovering sorbed
octreotide by two-phase extraction after rinsing with deionized water three times to remove
excess SDS. Octreotide was found to be stable after 24 hr incubation at 37◦C in all solutions.
6.2.5 Two-phase extraction of octreotide sorbed to PLGA 50:50
PLGA particles, sorbed with octreotide, were dissolved in 1 mL methylene chloride and the
octreotide was extracted with 2 mL acetate buffer (0.1 M, pH 4.0) three times. Octreotide
concentration was determined by HPLC.
6.3 Results and Discussion
6.3.1 Investigation of peptide sorption mechanism to PLGA from 24-
hr isotherms.
To determine the characteristics of peptide sorption to PLGA, such as the stoichiometry,
binding affinity, and maximal amount of peptide sorbed, 24-hour sorption isotherms were ob-
tained for two model peptides, octreotide and leuprolide (Figure 6.1). No true equilibrium is
typically reached for peptide sorption to PLGA, as several complicating dynamic phenomena
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occur upon incubation in aqueous solution, such as polymer hydration/swelling/plasticiza-
tion, rearrangement, hydrolysis, peptide acylation, and the release of soluble monomers
and oligomers. See below for possible exceptions. The net effect of these phenomena is to
alter the microenvironment of the polymer phase (e.g. water activity, free-volume between
polymer chains, dielectric constant, and diffusivity) and the total number of acid end-groups
with time, possibly affecting the surface potential and surface-to-bulk exchange of acid
end-groups. For these reasons, we chose a time (24 hours) where a pseudo-equilibrium has
been achieved (see Section 4.3.2).
The sorption of both peptides to PLGA were similar and behaved in a Langmuir-like
manner, increasing in a linear manner at low concentrations and transitioning to a satura-
tion point where the amount sorbed does not increase with additional increases in peptide
concentration. Octreotide sorption appears to have a slightly higher affinity to PLGA than
leuprolide, while leuprolide sorbs to a marginally greater extent at high concentrations.
It has previously been suggested that the presence of free carboxylates are a prerequisite
for octreotide sorption to PLGA [90]. This suggestion was validated by obtaining octreotide
sorption isotherms at neutral and acidic pH near the pKa of the PLGA carboxylic acids
(∼3.5), shown in Figure 6.2. Lowering the pH from 7.4 GA4.0 substantially inhibits octreotide
sorption, suggesting that the presence of ionized carboxylates is a necessary prerequisite
to octreotide sorption. However, it is also possible that pH may affect sorption through its
effect on the charge or solubility of the peptide or peptide-oligomer complexes. Note that
octreotide becomes completely dicationic (i.e. 1000:1 mole ratio of dication:monocation)
by pH 4.8.
The effect of the number of acid end-groups on octreotide sorption to PLGA was also
studied using a series of PLGA with varying molecular weights (see Table 3.1 for polymer
properties, including Mn), as shown in Figure 6.3. Sorption to RG 503H also followed
Langmuir-like behavior, while sorption to the higher molecular- weight RG 504H polymer
77
was minimal. As shown in Table 3.1, the total number of acid end-groups is reduced by 50%
from RG 502H GARG 503H, and another 50% from RG 503H GARG 504H. Interestingly,
the maximum amount of octreotide sorbed from the isotherms also appears to be reduced by
50% from RG 502H GARG 503H, although this is not the case for RG504H. It is possible
that above a certain molecular-weight, the PLGA microenvironment is substantially less
amenable to octreotide sorption, perhaps due insufficient polymer mobility, the reduction in
the diffusivity of oligomers, or differences in other factors mentioned above. For example,
reduced uptake and subsequent plasticization by water would lead to a higher hydrated Tg
relative to lower molecular-weight PLGA (recall that the dry Tg increases by 2–4◦C from
RG503H to RG504H, see Table 3.1). The trend of the sorption isotherms for RG502H and
RG503H in Figure 6.3 suggests that maximum sorption to PLGA may be governed by the
total number of acid end-groups in the polymer, while the unexpectedly low sorption for
RG504H appears consistent with microenvironmental factors such as polymer mobility also
playing an important role under certain circumstances.
6.3.2 Quantification of the maximal amount of peptide sorbed using a
modified Langmuir model
To further investigate the stoichiometry of peptide sorption to PLGA, the maximal amount
of peptide sorbed, Γmax, was estimated from the 24-hour sorption isotherms for octreotide
and leuprolide (Figure 5) by fitting the sorption data to the modified Langmuir equation by
non-linear regression (see Table 6.1):




where C f is the final concentration of peptide in solution, Γ is the amount of peptide sorbed,
Γ0 and Γ1 are model parameters related to the amount of peptide sorbed, Γmax = Γ0 + Γ1,
and K is the ’binding affinity’ in the classical sense described by Langmuir. The Langmuir
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Table 6.1 Langmuir model fitted parameters and estimated fraction of acids occupied at maximal
















Leuprolide RG 502H 0.77 1.5 229 185 1.24
Octreotide RG 502H 1.6 8.5 163 185 0.88
Octreotide RG 503H 1.2 2.9 81 94 0.86
Octreotide RG 504H n.d. n.d. ∼6c 53 n.d.
a Γmax = Γ0 + Γ1
b Fraction of Acids Occupied = Γmax / Total Acids
c Γmax estimated visually from isotherm
model requires that the adsorption process be reversible. Although Figures 6.1 and 6.3 show
typical reversible adsorption isotherms, most of octreotide sorption is irreversible at the
conditions tested (see Section 6.3.3, below). Such a tendency is often observed in the
sorption of peptides and proteins onto surfaces [165, 169], although the mechanism for this
remains unclear [170]. Therefore, the parameter K in Equation 6.1 does not imply the
adsorption affinity as defined in the original Langmuir equation. Nevertheless, it is common
to use Langmuir-type experiments to compare the binding of peptides and proteins to
surfaces and to estimate maximal surface coverage, regardless of the reversibility of the
process [165, 169].
As quantified in Table 6.1, the Γmax values for leuprolide and octreotide sorption to
RG502H, and octreotide sorption to RG503H appear to be approximately equal to the
total acid-content of the polymers (185 µmol/g for RG502H and 94 µmol/g for RG503H),
suggesting that in these polymers the peptides sorb until a 1:1 stoichiometry is attained.
The amount of acid end-groups was increased by pre-hydrolyzing the PLGA and de-
creased by incubating the PLGA in PBST buffer to release soluble monomers and oligomers.
The net change in the number of accessible PLGA end-groups is related to the amount
generated by polymer hydrolysis and lost by release of monomer and small oligomer impu-
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rities. Pre-incubating PLGA particles in PBST for 24 hr at 37◦C prior to octreotide sorption
resulted in an inhibition of the amount adsorbed by 49% relative to the amount predicted by
the Langmuir model, strongly suggesting that the number of accessible ionized end-groups
is decreased by pre-incubation with, and removal of, the PBST pre-incubation buffer. It is
likely that the acid content and possibly the zeta-potential of the particles was reduced after
pre-incubation via the release of monomers and soluble oligomers or PLGA.
The number of acidic end-groups in the PLGA was increased by pre-degrading the
PLGA in water for 24 hr at 60◦C. When the degraded PLGA was incubated with octreotide
solution, the amount adsorbed increased by 64% relative to the amount predicted by the
Langmuir model, suggesting that the amount adsorbed correlates with the number of acidic
end-groups. These results are consistent with the hypothesis that the extent of adsorption is
primarily due to the total number of acid end-groups in the polymer.
While we have not measured the zeta-potential of the polymer particles due to their large
size (>1 µm), the surface potential of PLGA particles is likely on the order of -70–80 mV,
based on zeta-potential measurements of PLGA nanoparticles and films. For the former, ζ =
-75 mV in 20 mM HEPES, pH 7.4 (Table 4.4) and for the latter, ζ = -70 mV in 1 mM KCl,
pH 7.5 (see Section 3.1.2). Assuming the particles have a zeta-potential near the values for
nanoparticles and films, the density of charges on the surface calculated using Equation 7.1
(see Section 7.3.2 below) is 65 nmol/m2, corresponding to 0.3 µmol/g, or 0.16% of the total
acids at the surface, based on a total surface area of 4.6 m2/g obtained from BET isotherms
(Section 3.1.1).
Furthermore, the surface area available for sorption of one molecule of octreotide at
maximal sorption was calculated to be 4.7 Å2. Based on a study of proteins at interfaces
[171], is has been estimated that an average amino acid occupies ∼15Å2 area on the surface
[167]. Given that it is highly unlikely that all of the acid end-groups are at the surface
or that peptide can adsorb at such high density, this result indicates that octreotide either
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forms a multilayer, precipitates with soluble oligomers, or partitions into the polymer phase.
Assuming no partitioning into the polymer, and that octreotide occupies a space equivalent
to the area of 4 average amino acids (∼60 Å2), monolayer coverage of octreotide would
require 12.7 µmol/g PLGA and a multilayer of∼13 layers would form at maximal octreotide
sorption to RG502H (163 µmol/g PLGA).
At this point, some indirect evidence suggests that following the initial adsorption,
octreotide may partition into the polymer phase: the 1:1 sorption stoichiometry of both
octreotide and leuprolide to RG502H and RG503H, and the curiously low sorption to high
molecular-weight RG504H. As previously mentioned, it is likely that RG504H, having a
Mn ∼5x greater than RG502H, is less mobile than RG502H or RG503H, possibly due its
increased dry Tg and reduced plasticization [40] resulting from decreased water uptake or
other factors affecting partitioning of octreotide into the polymer phase. While it is also
possible that octreotide forms multilayers on PLGA, if this were the case, the Langmuir-
like saturation of octreotide and leuprolide at values similar to the total number of acid
end-groups, would be a rather fortuitous result. Yet another possibility is that sorption
requires PLGA release of acid oligomers which would combine with the peptide to adsorb,
precipitate, and/or partition into the polymer phase. The physical state and localization of
sorbed octreotide is investigated further in subsequent chapters.
6.3.3 Effect of solution conditions on desorption of octreotide from
PLGA
Desorption studies were initially performed to investigate the appropriateness of an analysis
of peptide sorption using the Langmuir assumptions and later to investigate the nature of
the irreversibility. Various desorption solutions were chosen to selectively disrupt a variety
of molecular interactions. The high ionic strength and [Ca2+] in the 2M CaCl2 + HEPES
solution was intended to disrupt ionic interactions existing between octreotide and PLGA on
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the surface and compete for PLGA carboxylates, respectively. Similarly, trifluoroacetic acid
(TFA) was selected to potentially compete with PLGA carboxylates for octreotide amino
groups because it is more acidic than PLGA carboxylic acids, having a pKa = 0.2 versus
∼3.5 for PLGA. The acidic pH obtained using the Goods buffer diethylpiperazine (DEPP)
or acetate buffer (0.1 M, pH 4.0) should protonate some surface carboxylates, releasing
surface-bound ion-pairs, assuming that disrupting the ionic interaction is sufficient to desorb
octreotide. Desorption was also attempted at 4◦C because sorption was inhibited at this
temperature. None of these conditions tested led to substantial octreotide desorption, both
in absolute value (5% desorption) or relative to HEPES buffer control (Figure 6.4).
Poly(ethyleneimine) in 0.1 M acetate buffer, pH 4.0 resulted in the greatest extent of
desorption (15%) of the aqueous solutions tested, a 3-fold increase over the HEPES buffer
control (5%). Desorption of octreotide from PLGA in the presence of this solution may
have been enhanced simultaneously by a combination of several factors: protonation of
PLGA carboxylates, diffusion of acetic acid into the polymer phase, with concomitant
plasticization of the PLGA, increased ionic strength, competition for PLGA carboxylates
by PEI, and hydrophobic contacts between PEI and PLGA. The incomplete desorption of
octreotide from PLGA, despite of the large number of potentially disruptive interactions,
suggest these factors do not dominate the irreversibly of sorption. However, the addition of
5% SDS or organic solvent (50 vol% methanol in water) led to the desorption of 65±3%
and 55±5% of the originally sorbed octreotide, respectively, strongly suggesting the pre-
dominate interaction leading to irreversibly of sorption are hydrophobic contacts between
octreotide and PLGA. It is unclear whether methanol or SDS only act to desorb surface
associated octreotide, or whether they interact with octreotide that could potentially be
dissolved in the bulk polymer phase. Methanol can permeate into PLGA, plasticize and
swell the polymer, and potentially increase the solubility of the ion-pair in solution or the
diffusivity of the ion-pair within the bulk. It is also possible that the bulk polymer phase has
sufficient dielectric and permeability to support paritioning of the SDS into the PLGA.
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Octreotide sorption to the higher molecular weight RG503H polymer (see Table 3.1) was
also mostly irreversible. The amount of octreotide sorbed to RG503H is ∼1/2 of the amount
sorbed to RG502H (Figure 6.3 and Table 6.1), while the absolute amount of desorption from
both (33 nmol) was the same.
6.4 Conclusions
Octreotide desorption from PLGA was found to be no greater than 15% for various aqueous
solution conditions tested. Only the addition of 50 wt% methanol resulted in a substantial
desorption from PLGA, indicating the irreversibility was due to hydrophobic interactions or
hydrogen-bonding between the peptide and PLGA or low mass-transfer rates of absorbed
peptide-PLGA ion-pairs between bulk and the surface of the polymer. Although kinetically
irreversible, octreotide (and leuprolide) sorption follow Langmuir-like behavior. Sorption
of octreotide decreased as the pH of the solutions tested was decreased towards the pKa of
PLGA carboxylates. Reducing the number of total acid end-groups by increasing the PLGA
molecular weight also decreased octreotide sorption. These results indicate the critical
role of ionized PLGA acid end-groups during the peptide sorption pathway. Quantification
of the maximal amount of peptide sorbed at high solution concentration from a modified
Langmuir equation show that this number is similar to the total number of PLGA acid
end-groups for RG502H and RG503H, suggesting the possibility of peptide partitioning into
the polymer phase. The low amount of sorption to the higher molecular-weight RG504H is
also consistent with peptide partitioning into the polymer, as the decreased polymer mobility
with increasing molecular weight eventually prevents peptide partitioning. Future studies
will investigate this possibility in greater detail.
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Figure 6.1 24-hour sorption isotherms of leuprolide (◦) and octreotide (•) on PLGA 50:50
(Boehringer-Ingelheim RG 502H) in 0.1 M HEPES buffer, pH 7.4 at 37◦C.
Figure 6.2 Effect of pH on octreotide sorption to PLGA 50:50 (Boehringer-Ingelheim RG502H)
in solutions of 0.1 M HEPES buffer, pH 7.4 (N), 0.1 M MES buffer, pH 5.5 (), and 0.05 M DEPP
buffer, pH 4.0 (•) after 24 hours incubation at 37◦C.
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Figure 6.3 Effect of PLGA 50:50 molecular weight on 24-hr octreotide sorption isotherms at 37◦C
from solutions of 0.1 M HEPES buffer, pH 7.4. Boehringer-Ingelheim Resomer R© (•) RG 502H, (N)
RG 503H, and () RG 504H.
Figure 6.4 Desorption of octreotide from PLGA 50:50 particles and films (FH7) after 24 hr incu-
bation at 37◦C with 1 mM octreotide acetate in 0.1 M HEPES buffer, pH 7.4 (∼650 nmol octreotide
sorbed to RG502H particles (10 mg), ∼360 nmol to RG503H particles (10 mg), and ∼300 nmol to
RG502H Film D (30 mg)). Desorption solutions: 5 wt% SDS in water (SDS); 50 vol% methanol in
water (MeOH); 1 mg/mL PEI in 0.1 M acetate buffer, pH 4.0 (AP4); 0.1 M HEPES, pH 7.4 (3H7);
0.1% TFA in 0.1 M HEPES, pH 7.0 (TFAH7); 0.1 M DEPP, pH 4.0 (D4); 0.1 M HEPES, pH 7.4
(2H7: particles and FH7: films); 2 M CaCl2 in HEPES (HCa); 0.1 M HEPES, pH 7.4 (H4C). All
desorptions were at 37◦C, except H4C, which was at 4◦C. PLGA RG502H was used in all cases,




Octreotide Localization Upon Sorption
to PLGA
7.1 Introduction
It has previously been suggested that the presence of free carboxylates are a prerequisite
for octreotide sorption to PLGA [90]. Previous studies have shown that both octreotide
and leuprolide sorption to RG502H follows Langmuir-like behavior and saturates at values
near the number of total acid end-groups of the polymer (163 µmol/g PLGA). This was
also observed for octreotide sorption to RG503H, but not for RG504H. It is likely that
RG504H, having a Mw ∼5 times greater than RG502H, is less mobile than RG502H or
RG503H, due its increased dry Tg and reduced plasticization [40] resulting from decreased
water uptake. Furthermore, sorption to PLGA was shown to be significantly temperature
dependent, with no sorption observed at 4◦C (Section 5.3). These results are consistent with
peptide absorption into the bulk of the polymer or the requirement of oligomer release.
Assuming no partitioning into the polymer, and that octreotide occupies a space equiv-
alent to the area of 4 average amino acids (∼60Å2) (Section 5.3), monolayer coverage of
octreotide on PLGA particles would require 12.7 µmol/g PLGA and a multilayer of ∼13
layers would form at maximal octreotide sorption. Thus, the location of octreotide sorbed
to PLGA must either be exclusively within a multilayer, as a solid precipitate (for PLGA
particles), or partially absorbed within the bulk of the polymer. The specific aim of this
86
Chapter is to build on previous data suggesting peptide partitioning into the polymer and to
rigorously test this hypothesis.
In lieu of traditional methods used to study multilayer formation, such as in-situ el-
lipsometry, atomic force microscopy, or quartz crystal microgravimetry, which can be
complicated by polymer water uptake, swelling, hydrolysis, and rearranging, and may not
resolve whether peptides were present in the polymer phase, we chose to investigate the
possibility of octreotide partitioning into PLGA by attempting to physically localize the
peptide in the polymer phase. In this Chapter, this is done by investigating the solubility of
sorbed octreotide in organic solvent, study the effect of film thickness on peptide sorption,
recover peptide from sectioned films, and perform x-ray photoelectron spectroscopy (XPS)
surface analysis on PLGA films.
7.2 Materials and methods
7.2.1 Materials
Octreotide acetate was obtained from Novartis (Basel, Switzerland). PLGA 50:50
(Resomer R© RG502H) was purchased from Boehringer-Ingelheim GmbH (Ingelheim, Ger-
many). d3-Acetonitrile and d6-dimethylsulfoxide were obtained from Cambridge Isotope
Laboratories (Andover, MA). All other reagents used were of analytical grade or purer and
purchased from commercial suppliers.
7.2.2 PLGA film preparation and characterization
PLGA film preparation and characterization by SEM was described in detail in Section
3.1.2. Briefly, PLGA in acetone solutions were placed on glass (for film thickness study) or
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gold coated glass substrate (for XPS analysis) and spread using a spin coater (SCS G3-8,
Indianapolis, IN). See Table 3.2 for the conditions used to spin-coat PLGA solutions onto
glass microscope cover-slides. Following spin-coating, nascent PLGA films were dried for
48 hr at room temperature and pressure followed by 24 hr in a vaccum oven at 40◦C.
7.2.3 Analysis of octreotide solution concentration by HPLC
The concentration of octreotide was determined by HPLC, by loading solutions (20 µL)
onto a Nova Pak C-18 column (3.9 x 150 mm, Waters) for RP-HPLC (Waters Alliance R©)
analysis using UV for detection (280 nm). Solvent A: 0.1% TFA in acetonitrile; Solvent B:
0.1% TFA in water; Linear gradient: 25 to 35% A in 10 min.
7.2.4 Sorption of octreotide to PLGA films
Solutions of octreotide (1 mM, 4.5 mL) in HEPES buffer (0.1M, pH 7.4) were added to
PLGA films of varying thicknesses (2, 7, 13, 24, and 40 µm) with constant surface area
(see Section 3.1.2 for detailed description of manufacturing method) placed in a Petri-dish
with tight-fit lid (Beckton-Dickinson, Franklin Lakes, NJ) and incubated at 25 and 37◦C
for 24 hr. After incubation, the amount of octreotide sorbed was determined by recovering
sorbed octreotide via two-phase extraction. PLGA films were first broken and placed within
a 15 mL polypropylene centrifuge tube prior to extraction. The films were then dissolved
by adding methylene chloride (1 mL) and using 50 mM acetate buffer, pH 4.0 (2 mL),
followed by a second extraction with acetate buffer containing 1 M NaCl, which was useful
to minimize saponification. The extracts were pooled and analyzed by HPLC as described
in Section 7.2.3.
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7.2.5 1H Nuclear magnetic resonance of sorbed octreotide
Solutions of 1 mM octreotide (1 mL) in HEPES buffer were added to PLGA particles, as
received (10 mg), and incubated at 37◦C on a rotary shaker (320 rpm). After sorption,
samples were removed from the incubator, centrifuged, the supernatant was removed, and
the PLGA was rinsed with deionized water. PLGA-octreotide was freeze-dried, dissolved
in d3-acetonitrile (1 mL, Cambridge Isotope Laboratories, Andover, MA), and filtered
(Millipore Millex R©-FG PTFE syringe filter, 0.2 µm pore diameter) prior to NMR analysis
(Bruker Avance DRX500). As controls, PLGA and octreotide were dissolved individually
in d6-dimethylsulfoxide.
7.2.6 Sectioning and analysis of PLGA films sorbed with octreotide
PLGA films were cast onto specially prepared plastic cylinders (8 x 13 mm) for microtoming.
To achieve even sectioning of the PLGA films, a 2 x 2 mm circular groove was cut out
from the 8mm diameter face to leave a 4 mm diameter face. The PLGA film was cast by
placing 4 µL of a 22% PLGA in acetone solution on the 4 mm diameter face of the plastic
cylinder. The films were then dried at room temperature for 24 h, then for another 24-48 h
in a vacuum oven at 40◦C. Cylinders with PLGA films were then immersed into 2 mL of
0.5 mM octreotide acetate in 0.1 M HEPES, pH 7.4 and incubated for 24 h at 37◦C. After
incubation, the films were removed from the octreotide solution, rinsed, and dried for 24-48
h in a vacuum oven at 40◦C. The dried films were then sectioned using a Reichert Ultracut-E
ultramicrotome (Vienna, Austria). The films were viewed through the microscope on the
Ultracut-E and appear to have a very rough morphology as well as some curvature. The
thickness of the film was estimated to be ∼80 µm by slicing through the entire film in 0.5
µm increments. Two groups of 5-7 films were cut to a depth of ∼20 µm and ∼40 µm. Each
group sectioned films, as well as a non-sectioned control, were then carefully dissolved
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together in 1 mL methylene chloride and extracted similarly as described in Section 4.2.7
prior to HPLC analysis with detection at 215 nm.
7.2.7 Surface analysis by x-ray photoelectron spectroscopy
XPS analysis of PLGA films on gold-coated glass cover-slides was performed using a
Kratos AXIS spectrometer in constant analyser energy transmission mode. Gold-coating
was performed as a safeguard against detection of elements in the glass substrate or to
indicate the presence of film defects. The source employed was monochromated Al Ka
radiation (1486.6 eV) with a photoelectron take-off angle of 90◦ to the surface, operated at
10 mA emission current and 15 kV anode potential. A low-energy electron flood gun was
employed for charge neutralisation. High resolution scans of the C 1s and O 1s core levels
were obtained with a pass energy of 20 eV. Atomic compositions were calculated based
on atomic sensitivity factors obtained from Reference [172]. Data analysis was performed
using Casa XPS version 2.3.14.
7.3 Results and Discussion
7.3.1 1H-NMR of octreotide-PLGA ion-pair dissolved in d3-acetonitrile
The presence of sorbed octreotide in acetonitrile was assessed by 1H-NMR in order test
the hypothesis that the octreotide-PLGA ion-pair would have enhanced solubility in low-
dielectric solvents, a condition that would appear to be required for partitioning into the bulk
of the polymer phase. The characteristic proton shifts at 6.7–7.5 ppm attributable to protons
on the aromatic side chains of octreotide [173] present in the octreotide control sample also
appear in the test sample containing PLGA incubated with octreotide in acetonitrile (Figure
7.1). As free octreotide acetate is not soluble in acetonitrile, the presence of the characteris-
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tic octreotide proton shifts in the test sample indicate that octreotide is solubilized by the
formation of a PLGA-octreotide ion-pair, confirming the hypothesis that upon ion-pairing
with PLGA, the solubility of octreotide increases in low dielectric solvent.
7.3.2 Peptide sorption to PLGA films
The localization of sorbed octreotide, whether adsorbed as multilayer or absorbed within the
bulk of the polymer, was investigated using PLGA films with constant surface area (12.6
cm2) of varying mass and thickness (2, 7, 13, 24, 40 µm). The amount of octreotide and
leuprolide sorbed to PLGA films at 37◦C increased linearly with the amount of PLGA added
(e.g. film thickness) with an approximate slope of 9.7 nmol/mg PLGA (Figure 7.4). Negligi-
ble octreotide sorption was observed at 22◦C, a temperature likely below the glass-transition
temperature of the hydrated PLGA film, suggesting that the mobility of the polymer is likely
necessary for octreotide sorption to PLGA. Interestingly, sorption at 30◦C showed biphasic
behavior, increasing linearly for thin films and plateauing for thicker films, suggesting this
temperature is near the Tg, although thickness-dependent surface compositional effects
could potentially play a role [160]. At temperatures near the glass-transition temperature,
the reduced polymer mobility could limit peptide sorption by either prohibiting the release
of oligomers or decreasing the diffusivity of both the polymer and peptide-polymer adduct
in the polymer phase.
The effect of film thickness on octreotide sorption could potentially be a result of differ-
ences in release of acid oligomers, different chemical composition of the surface layer, film
thickness total surface area (e.g. due to roughness), or differences in the surface-potential.
Using ATR-FTIR spectroscopy, Thanki et al. [160] found that in PLGA films, thicker
films (46 µm) contained a larger number of methyl side chains from the lactic acid units at
the polymer/air surface than thinner films (< 2 µm) and the population of methyl side groups
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on the film surface decreased with decreasing the film thickness. The reduced number of
methyl groups on the surface for thin films was attributed to the decreased availability of
bulk polymer that can provide methyl groups to the surface.
Thanki et al. [160] also found, based on contact angle relaxation measurements, that
15 µm-thick films with relatively higher number of hydrophobic groups on the surface,
relative to 1 µm-thick films, rapidly undergo restructuring as their surface comes into con-
tact with water, with the methyl side chains orientating away from the interface. This was
not observed for thin films, indicating that potential for conformational rearrangement in
PLGA is thickness-dependent. Although it is possible that thickness effects could play a
role in differences in the surface composition between the thinnest films studied and the
thicker ones, this effect is unlikely to be significant at the 13, 24, and 40 µm thicknesses.
Furthermore, the extremely linear relationship at 37◦C between the amount of octreotide
sorbed and film thickness over the entire range of thicknesses studied strongly suggests that
surface compositional effects were insignificant.
The morphology of hydrated PLGA films in the absence of octreotide was generally
smooth (Figure 7.2(a)). The addition of octreotide resulted in the formation of circular areas
of rough morphology (Figure 7.2(b)), increasing in diameter and density with increasing
film thickness. It could be possible that the increased sorption with increasing film thick-
ness could result from the increased total surface area of the hydrated PLGA. We estimate
that ∼35 nmol octreotide would form monolayer coverage on the 4 cm diameter films (2.8
nmol/cm2), based on an analysis similar to the one performed in Section 6.3.2. The estimated
value of 35 nmol octreotide per monolayer corresponds to 12 monomer thicknesses for
Film E, the thickest film studied, which sorbed 418 nmol octreotide. Assuming a multilayer
20 monomers thick and no partitioning into the polymer phase (e.g. 55.4 nmol/cm2), the
surface area of the 7, 13, 24, and 40 µm thick PLGA films would need to increase by 1.3,
2.9, 5.6, and 8.6 times the surface area of the 2 µm film to account for the observed increase
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Table 7.1 Effect of zeta-potential on solution concentration at the surface in [mM], calculated using














in peptide sorption at 37◦C.
It is also possible that increasing the thickness of PLGA films could affect the zeta-
potential, as thicker films have a larger content of acid end-groups, which may be prefer-
entially presented at the surface. The following relationship between ψ0, the electrostatic
potential in the aqueous phase at the surface, and σ , the charge density, derived from the




C = sinh(zeψ0/2kT ) (7.1)
where k is the Boltzmann constant, T is the temperature e is the electronic charge, z is the
valence of the electrolyte, C is the bulk electrolyte concentration, and A = 1/(8Naεε0kT )1/2,
where Na is Avogadro’s number, ε is the dielectric constant, and ε0 is the permittivity of free
space. A 5 mV change in zeta-potential only changes the total number of charges on the
surface by 10 pmol, far to little to account for the >50 nmol increment in peptide sorbed
(Figure 7.4).
The surface concentration Cs can be related to the bulk concentration Cb using the
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Boltzmann factor as shown in the following expression:
Cs = Cb exp(zieψ0/kT ) (7.2)
where zi is the valency of the ion in solution. A 1mV difference in zeta-potential has
a significant impact on the solution concentration of the peptide at the surface, especially
when zi = 2. For the divalent octreotide, a 1 mV increment in zeta-potential can increase the
surface concentration by 15–20-fold relative to the bulk concentration and by 8% relative
to the surface concentration (Table 7.1). This effect is less significant for the monova-
lent leuprolide. If the increased peptide sorption were explainable as resulting from the
effect of zeta-potential on Cs, we would not expect to observe similar sorption behavior
between divalent octreotide and monovalent leuprolide (e.g. in the slope of sorption plots
with mass/thickness, see Figure 7.4). Thus, we conclude that the effect of PLGA film
mass/thickness cannot be explained by differences in film zeta-potential.
7.3.3 Localization of sorbed octreotide within PLGA
An additional experiment was performed to confirm that the peptide was partitioning into
the polymer phase. PLGA films were incubated in the presence of octreotide solution and
sectioned prior to recovery by two-phase extraction. The results of two pools of 5-7 4 mm
diameter films ∼80 µm thick are shown in Table 7.2. Between 73-80% and 60-65% of
the amount of octreotide sorbed to the control film was recovered after, removing roughly
25% and 50% of the top section of the PLGA film. Due to substantial surface roughness,
the starting point for sectioning may have varied somewhat between samples. Also, the
films displayed some curvature due to edge effects on the small substrate. Due to this, as
well as exposure of the side of the film to the octreotide solution, it was likely that some
of the recovered octreotide was present on the surface of the remaining film. Nevertheless,
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Table 7.2 Octreotide recovery from sectioned PLGA films incubated in the presence of 1 mM
octreotide acetate solution.




it is unlikely that the large amount of remaining octreotide is only an artifact of these
observations and not partially due to peptide solubility in the bulk polymer phase.
7.3.4 Surface analysis by X-ray Photoelectron Spectroscopy
The wide-scan survey spectrum covering the binding energy range of 0-1000 eV with a
pass energy of 160 eV showed that only carbon and oxygen were present and that, prior
to incubation, PLGA films were free from any unexpected elements within the top ∼10
nm of the polymer surface (Figure 7.5). The atomic composition of PLGA and octreotide
powder were calculated from the XPS high resolution spectra and compared to their the-
oretical compositions (see Figure 7.6 for octreotide survey spectrum). As shown in Table
7.3, the calculated atomic compositions for both PLGA and octreotide closely matched the
theoretical atomic compositions, validating that the atomic sensitivity factors [172] used
were accurate.
The XPS spectrum of a PLGA film prepared according to D conditions after incubation in
1 mM octreotide acetate solution showed the presence of nitrogen, sulfur, and trace sodium,
indicating that sorbed octreotide is present in the top layer of the film (Figure 7.7). The cal-
culated atomic compositions for the spectrum was intermediate between pure PLGA and oc-
treotide, consistent with the presence of∼40% octreotide in the top-most∼10 nm of the film,
estimated by least-squares minimization of the atomic compositions Xi using the equation:
Xi = Xi,octFoct + Xi,plgaFplga, where Xi,oct and Xi,plga are the atomic compositions of pure
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Table 7.3 Atomic compositions of PLGA films determined from XPS spectra shown in Figures 7.5
– 7.7. Trace amounts of sodium were not included.
Sample Calculated Composition (%) Theoretical Composition (%)
C O N S C O N S
PLGA control 57 43 — — 56 44 — —
octreotide control 68 16 13 3 69 14 14 3
PLGA + 1mM octreotidea 65 29 4 2 — — — —
a Standard Deviation (n=2): C(1.1), O(3.4), N(0.7), S(1.6)
octreotide or PLGA, and Foct and Fplga are the mole fraction present in the layer analyzed
by XPS.
7.4 Conclusions
In this study, we investigated the solubility properties of ion-paired octreotide-PLGA in
two low-dielectric mediums, acetonitrile and PLGA. The presence of octreotide-PLGA in
acetonitrile was confirmed by 1H-NMR, and absorption of octreotide into PLGA is strongly
suggested by the increased sorption with increasing polymer thickness, which is unlikely due
to differences in surface roughness or zeta-potential. A second experiment where octreotide
was recovered from sectioned PLGA films is also consistent with octreotide absorption
within PLGA. However, XPS analysis suggests the composition of octreotide in the 10
nm-surface layer is 40 mol%. Hence, currently data supports both absorption and multilayer
adsorption.
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Figure 7.1 1H-NMR of PLGA 50:50 in d6-dimethylsulfoxide (top), sorbed octreotide-PLGA 50:50
in d3-acetonitrile (middle), and octreotide acetate in d6-dimethylsulfoxide (bottom).
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Figure 7.2 Scanning electron micrograph of the surface of a PLGA 50:50 film prepared according
to A conditions (see Table 3.2) after 24 h incubation in 0.1M HEPES buffer, pH 7.4 A without and B
with 1 mM octreotide acetate at 37◦C.
98
Figure 7.3 Scanning electron micrograph of the surface of a PLGA 50:50 film prepared according
to C conditions (see Table 3.2) after 24 h incubation with 1 mM octreotide acetate in 0.1 M HEPES
buffer, pH 7.4 at 37◦C.
Figure 7.4 Effect of mass/thickness on peptide sorption to PLGA 50:50 (Boehringer-Ingelheim
RG502H) films in 0.1 M HEPES buffer, pH 7.4 at 22◦C (octreotide: •), 30◦C (octreotide: N), and
37◦C (octreotide: 4, leuprolide: ). Initial peptide concentration was 1.0 mM.
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Figure 7.5 The XPS survey spectra of a PLGA 50:50 film prepared according to D conditions (see
Table 3.2).
Figure 7.6 The XPS survey spectra of octreotide acetate powder.
100
Figure 7.7 The XPS survey spectra of a PLGA 50:50 film prepared according to D conditions (see




This dissertation has focused on understanding peptide sorption to PLGA mechanistically,
with the goal of utilizing this understanding for a rational formulation approach to stabi-
lize octreotide and similar peptides against acylation within PLGA controlled release drug
delivery systems. Surprisingly, these studies are the first detailed investigations of peptide
sorption to low molecular-weight free-acid PLGA, perhaps due to the challenges these
polymers present (e.g. water uptake and degradation) preventing straight-forward use of
many traditional methods used to study sorption behavior.
A new class of inhibitors of the sorption and acylation of a model peptide, octreotide,
has been described. Long-term sorption studies in the presence of CaCl2 and MnCl2 indi-
cated that disrupting peptide sorption to PLGA with the inorganic divalent cation inhibitors
translates to inhibition of peptide acylation. Acylation of octreotide encapsulated in PLGA
millicylinders containing equivalent weight ratio CaCl2 or MnCl2 relative to peptide was
also inhibited relative to no salt or NaCl controls both during encapsulation or release
incubation.
We have shown that the octreotide-PLGA interactions are mostly kinetically irreversible
in aqueous solutions and changes the solubility properties of octreotide in acetonitrile,
confirmed by 1H-NMR. Only the addition of solvent or 5% SDS resulted in a substantial
desorption from PLGA, strongly suggesting the irreversibility was due to hydrophobic
interactions or hydrogen-bonding between the peptide and PLGA or low mass-transfer rates
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of absorbed peptide-PLGA ion-pairs between bulk and the surface of the polymer.
The kinetic profiles of peptide sorption to PLGA were also investigated at various solu-
tion conditions. The rate and extent of sorption is reduced at low octreotide concentrations,
high solution ionic strength and low temperature, becoming completely attenuated at 4◦C,
suggesting polymer mobility plays a critical role in the sorption interaction. A biexpo-
nential model described the sorption profiles extremely well, and a relationship between
concentration and the model parameters is obvious, although further research will need to
be conducted in order to discern this relationship.
Although kinetically irreversible, octreotide (and leuprolide) sorption follow Langmuir-
like behavior. Sorption of octreotide decreased as the pH of the solutions tested was
decreased towards the pKa of PLGA carboxylates. Reducing the number of total acid
end-groups by increasing the PLGA molecular weight also decreased octreotide sorption.
These results indicate the critical role of ionized PLGA acid end-groups during the peptide
sorption pathway. Quantification of the maximal amount of peptide sorbed at high solution
concentration from a modified Langmuir equation show this value to be similar to the total
number of PLGA acid end-groups for RG502H and RG503H, suggesting the possibility of
peptide partitioning into the polymer phase or dependence on acid release from the polymer.
The low amount of sorption to the higher molecular-weight RG504H is also consistent with
peptide partitioning into the polymer, as the decreased polymer mobility with increasing
molecular weight eventually prevents peptide partitioning.
The localization of sorbed octreotide, whether adsorbed as multilayer, precipitated,
or absorbed within the bulk of the polymer, was directly investigated using PLGA films
with constant surface area of varying thickness and by recovering sorbed octreotide from
sectioned PLGA films. These studies strongly suggest that some peptide is indeed absorbed
within the bulk of the polymer. While we cannot completely rule out the presence of some
multilayer sorption or precipitation, the calculations presented in this dissertation suggest
103
that multilayer sorption alone cannot support the large body of evidence consistent with
internalization of octreotide within PLGA.
There have been no prior reports of peptide internalization into the PLGA phase, making
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